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1 Introduction 
1.1 Gene Therapy 
Conventional treatment of monogenic diseases like Cystic Fibrosis aims mainly at 
relieving the symptoms rather than addressing the cause of the disease. Somatic 
gene therapy in contrast could be used to complement a defective gene with a 
functioning one in order to cure the disease, slow its progression, or even prevent its 
onset. Other approaches in gene therapy involve the treatment of complex diseases 
like cancer. Here, the cause of the disease is addressed for example by transferring 
genes that interact with cell proliferation or genes that encode for immune stimulatory 
factors. 
In both cases, the basic principle relies on the transfer of genetic material (genes or 
cDNA) to host cells that are either directly involved in the disease or can effect its 
course. Transfer can be achieved by in vivo or ex vivo methods. In vivo gene therapy 
implies the transfer of genetic material to cells by suitable vectors directly inside the 
organism. Using the ex vivo approach, cells – e.g. haematopoietic stem cells – are 
taken out of the body, the expression cassette for the therapeutic transgene is 
introduced in vitro, and the recombinant cells are transferred back into the host. Both 
methods have advantages and disadvantages. The ex vivo approach offers more 
efficient gene transfer and the possibility to control and select successfully 
manipulated cells. It is, however, patient specific due to the requirement of 
histocompatible cells, which renders the process more costly. In vivo gene transfer, 
in contrast, is less expensive, easier to handle and not patient specific, but also less 
efficient.  
Essential for all gene therapy approaches are efficient vector systems. Such vectors 
can grossly be divided into viral and non-viral vectors. So far, viral vectors are 
superior to non-viral vectors in terms of transfection efficiency, transgene expression 
levels and duration of expression. This is also represented by the fact that 70% of 
clinical protocols involve viral gene delivery vectors (Fig. 1.1). Of these, 53% employ 
retroviruses or adenoviruses (discussed below). 
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Fig. 1.1: Frequency of use of different vectors in gene therapy clinical trials. 
 
Non-viral vectors comprise mainly naked DNA (notably used in 15% of gene therapy 
clinical trials), or DNA complexed with cationic liposomes or polymers. Recently, also 
intracellular bacteria have emerged as potential gene delivery systems.  
The criteria for an ideal gene therapy vector are reviewed below (from [157]). 
 
Easy production 
The vector should be easy to produce at high titre on a commercial scale. This consideration stems 
from the wide range of cell numbers that must be transduced — from a handful of stem cells capable 
of reconstituting the entire haematopoietic repertoire to 1011 or more cells to infect 5–10% of 
hepatocytes in the liver. For widespread use, the vector should be amenable to commercial production 
and processing (such as concentration technology for delivery in small volumes), and should have a 
reasonable shelf-life for transport and distribution. 
 
Sustained production 
The vector, once delivered, should be able to express its genetic cargo over a sustained period or 
expression should be regulable in a precise way. Different disease states have different requirements 
(for example, regulated expression in diabetes and lifetime expression in haemophilia). 
 
Immunologically inert 
The vector components should not elicit an immune response after delivery. A humoral antibody 
response will make a second administration of the vector ineffective, whereas a cellular response will 
eliminate the transduced cells. 
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Tissue targeting 
Delivery to only certain cell types is highly desirable, especially where the target cells are dispersed 
throughout the body (such as in the haematopoietic system), or if the cells are part of a heterogeneous 
population (such as in the brain). It is also important to avoid certain cells, such as dendritic cells, the 
“professional” antigen-presenting cells of the body, because of their role in mediating the immune 
response. Cell or tissue-targeted vectors present a great challenge, but also offer rich dividends for 
gene therapy approaches. 
 
Size capacity 
The vector should have no size limit to the genetic material it can deliver. The coding sequence of a 
therapeutic gene can vary from 350 base pairs for insulin, to over 12,000 base pairs for dystrophin. 
Furthermore, addition of appropriate regulatory sequences may be required for efficient transduction 
and expression of the foreign genetic material. 
 
Replication, segregation or integration 
The vector should allow for site-specific integration of the gene into the chromosome of the target cell, 
or should reside in the nucleus as an episome that will faithfully divide and segregate on cell division. 
Site-specific integration is a very desirable attribute because it eliminates the uncertainty of random 
integration into the host chromosome, and endogenous regulatory regions will control its expression 
under physiological conditions. The ability of the vector to be maintained as an episome could make 
the genetic elements independent of local chromatin environments, but faithful replication and 
segregation is needed if the vector is to be effective in systems such as stem cells. 
 
Infection of dividing and non-dividing cells 
As large numbers of cells (such as neurons, hepatocytes and myocytes) are postmitotic, vectors 
capable of efficiently transducing non-dividing cells are very desirable. 
 
So far, no vector is available that matches all the criteria. Rather, different vectors are 
designed to fit special requirements.  
1.2 Viral vectors 
Viral vectors are derived from modified viruses in which genes essential for 
propagation are replaced by the transgene. The essential genes can be provided in 
trans by a so called packaging or helper cell, leading to the generation of viral 
particles that are infectious and can introduce their genetic material into a recipient 
cell. However, due to the lack of the essential genes, it cannot replicate any further. 
Viral vectors can be divided into two categories: integrating and non-integrating. The 
group of integrating vectors mainly comprises retroviral, lentiviral and adeno-
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associated viral vectors [157]. These are especially suitable for life-long expression 
of the transgene, as required for complementation of genetic defects like Cystic 
Fibrosis or diabetes. Adenoviral vectors, in contrast, are maintained in the recipient 
cell as an episome.  
Retroviral vectors 
Retroviruses are positive-sense single-strand RNA viruses. After introduction of their 
genetic material into the host cell, reverse transcription of the viral genome into 
double-stranded DNA is initiated. Subsequently, the DNA is integrated into the 
genome of the host cell and the viral proteins needed for propagation are expressed. 
Retroviral vectors were among the first gene therapy vectors to be designed.  
Usually, retroviral vectors consist only of long terminal repeats (LTRs) and a 
packaging function but lack the gag (encoding viral structural proteins), pol (encoding 
reverse transcriptase/ integrase) and env (encoding viral envelope glycoprotein) 
genes. These essential proteins are provided by a packaging cell in trans during the 
manufacture of the retroviral vector. Separating gag and pol from env in the 
packaging cell significantly reduced the risk of generating replication-competent virus 
by recombination of the different gene segments. Meanwhile, a wide variety of 
packaging cell lines and vectors are available, equipped with particular features such 
as tissue specific or inducible promoters and env proteins with modified target 
specificity. However, retroviral vectors have one major restriction: they can transduce 
only dividing cells because the linear DNA that is synthesized during the viral 
infection is unable to penetrate the intact nuclear membrane. Hence, organs like 
brain, lung, pancreas or the eye are not accessible to in vivo gene transfer. 
Nevertheless, retroviral vectors are still extensively used to transduce dividing cells 
such as tumour cells or haematopoietic cells [157].  
Lentiviruses like HIV belong to the family of retroviruses, but have the unusual 
property to transduce dividing as well as non-dividing cells. Consequently, systems 
based on lentiviruses have been developed. In the first generation, the env protein 
was substituted by vesicular stomatitis virus G protein (VSVG), relieving these 
vectors of their dependence on CD4. However, concerns were raised because of the 
possibility of generation of infectious HIV by recombination. To address this issue, 
many viral accessory genes were deleted, such that the latest lentiviral vector 
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systems retain less than 25% of the viral genome in the packaging construct and less 
than 5% of the viral genome in the vector construct [76; 189]. The improved vectors 
are able to transduce a wide variety of host cells. Data from clinical trials using 
lentiviral vectors are currently not available and the duration of transgene expression 
from these vectors also needs further testing.  
Adenoviral vectors 
Adenoviruses are double-stranded DNA viruses that cause respiratory tract infection 
in humans. These viruses exhibit a broad host range and cell tropism. Replication-
defective adenoviral vectors have been generated by deleting several viral genes, 
and high titre preparations of these recombinant vectors can be produced with 
relatively little effort.  
A big advantage of adenoviral vectors over retroviral vectors is their ability to 
transduce dividing as well as non-dividing cells. In the host cell, the adenoviral 
genome is maintained as an episome in the nucleus. Therefore the major obstacle of 
adenoviral vectors for general use concerns the persistence of transgene expression. 
With the first generation of adenoviral vectors, sustained transgene expression was 
observed only in long lived cells (such as muscle cells and neurons) in immuno-
compromised animals, while in immuno-competent individuals an immune response 
was raised against the recombinant adenoviral vector. Cellular immune responses 
eliminated the transduced cells, while humoral immunity prevented repeated 
administration of the vector [26; 77]. For these reasons, adenoviral vectors are 
mainly used for applications that require high level but transient transgene 
expression, like anti-cancer therapy. 
In the more advanced form, the so called “gutless” adenoviral vectors, the viral 
protein encoding sequences have been deleted and are provided in trans by a helper 
virus [83; 121]. With these vectors, the above mentioned problems appear to be 
solved, and long term maintenance of the transgene has been observed in several 
organs and different species (reviewed in [64; 84]).  
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1.3 Non-viral vectors 
The major advantages of non-viral vectors are their simplicity of use, ease of large 
scale production and lack of initiation of a specific immune response against the 
vector [95]. Safety concerns about the use of viral vectors in humans render these 
delivery systems a serious alternative. The major limitations of the non-viral vectors 
are their relatively low transfection efficiency as compared to viral vectors and the 
short duration of transgene expression. To achieve more efficient gene transfer, the 
plasmid DNA was complexed together with cationic liposomes or polymers. This has 
improved transfer efficiency in vitro. In vivo, however, the effect is strongly dependent 
on the route of administration. Some efforts have been made to compensate for 
these restrictions, including the development of episomal vectors for prolonged 
transgene expression, and cytoplasmic expression vectors to circumvent the 
necessity of nuclear transport of the DNA, thereby enhancing the number of cells 
expressing the gene of interest. 
An interesting aspect of direct gene transfer was discovered by Wolff and co-workers 
in 1990. They described direct gene transfer after intramuscular injection of plasmid 
DNA into mice [184]. This elicited an efficient immune response against the antigen 
encoded by the vector. Subsequently, this approach has been used to express a 
wide range of antigens, in particular viral and tumour antigens, thereby protecting 
mice against various infectious agents and tumour challenges. This phenomenon has 
been named “DNA vaccination”. The efficiency of gene transfer via naked DNA was 
further improved by alternative physical application methods, such as electroporation 
and the use of a gene gun. 
1.4 Bacteria-mediated gene transfer to mammalian cells 
As mentioned before, vector systems used so far suffer from low transfection 
efficiencies in vivo and/ or sometimes even raise safety concerns. Recently, 
intracellular bacteria emerged as a new class of vectors for gene delivery to 
mammalian cells and might be established as serious alternative to the commonly 
used systems (reviewed in [97]). The first direct transfer of plasmid DNA from 
Escherichia coli to a mammalian cell was described already in 1980 by Schaffner 
[142]. In the meantime, several invasive bacteria have been used for gene transfer 
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approaches, including attenuated strains of the Gram-negative species Salmonella 
typhimurium and Shigella flexneri, the Gram-positive bacterium Listeria 
monocytogenes as well as engineered invasive Escherichia coli, to name the species 
studied most extensively. It should be mentioned here that also non-invasive bacteria 
like Agrobacterium tumefaciens are able to directly transfer DNA to eukaryotic host 
cells by using their conjugation apparatus [90]. 
In all protocols in which invasive bacteria are used to date, the transfer of genetic 
material to the host cell is dependent on the death and lysis of the bacterium inside 
the cell. This can be achieved by different methods. In the first studies, auxotrophic 
mutants of S. flexneri with a disrupted asd gene encoding an essential component for 
the synthesis of the bacterial cell wall were used [22; 153]. Other protocols involved 
bacteriophage lysis components or, as in our own protocol, antibiotics were used to 
induce bacterial death [29; 60]. Spontaneous transfer of plasmid DNA from wild type 
bacteria has been reported as well [55; 88]. In that case, death of the bacteria might 
have been induced by host cell defence mechanisms or temperent phages.  
The mechanism of DNA transfer from different bacteria is shown schematically in 
Fig. 1.2. Escape from the phagocytic vacuole to the cytoplasm of the host cell by 
production of membrane disrupting toxins is a characteristic shared by Listeria and 
Shigella. Once in the cytoplasm, the lysis of the bacteria is induced and the plasmid 
load can be released. In the case of Listeria, escape from the vacuole was shown to 
be essential for gene transfer to take place [60]. Salmonella and some of the E. coli 
strains used, however, do not share this feature [97]. After invasion of the cell, these 
bacteria remain in the vacuole. Nevertheless, they mediate transfection of host cells 
after induction of bacterial lysis. How the transfer of plasmid DNA in this case is 
occuring is not yet understood. Also, the mechanism by which the plasmid DNA 
eventually reaches the nucleus is not clear.  
Different bacteria exhibit different host cell specificities in vitro with regard to their 
ability to mediate gene transfer. Salmonella, for example, transfect in vitro only 
primary murine and human macrophages and to some extend dendritic cells [15; 27; 
49; 55]. This specificity renders them especially suitable for genetic vaccination. In 
contrast, L. monocytogenes and invasive E. coli are able to transfect various cell 
lines mainly of epithelial origin, but have also been shown to act on primary cells [55]. 
Salmonella-mediated transfection of cells other than macrophages can be achieved 
by conferring constitutive secretion of Listeriolysin O (LLO), the pore forming toxin of 
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L. monocytogenes, to the bacteria. This allowed the recombinant Salmonella to 
escape from the phagosome, similar to Listeria [49].  
 
 
 
 
Fig. 1.2: Principles of bacteria-mediated gene transfer to eukaryotic host cells (from [183]). A) Some 
intracellular bacteria like L. monocytogenes or S. flexneri can escape from the phagosome after entry 
of the host cell. They lyse and release their plasmid DNA into the cytosol. B) Other bacteria like 
Salmonella or invasive E. coli are unable to escape from the phagosome and are lysed within this 
vesicle. How the plasmid DNA is transported to the cytosol is unknown. C) In both cases, the plasmid 
reaches the nucleus where the transgene is transcribed and later, in the cytosol, translated into the 
protein of interest.  
 
Bacteria as vectors for gene transfer have several advantages, including the different 
host tropisms mentioned above. Many bacteria (as well as the plasmid DNA they 
carry) are genetically easy to manipulate. Furthermore, the bacterial carrier and the 
plasmid to be transferred are distinct entities that can be modified independently, 
allowing the combination of different properties. The production and handling of 
bacterial vectors is simple and inexpensive. Most importantly, bacteria like Listeria or 
Shigella, that can spread from cell to cell, might be able to reach deeper tissue layers 
in vivo which are not accessible to immobile synthetic or replication incompetent viral 
vectors.  
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So far, the main focus in the field of bacteria-mediated gene transfer has been 
directed to genetic vaccination. In this approach, the genetic information for an 
antigen of a particular pathogen is delivered to the host, where it is expressed and a 
specific immune response is triggered. Bacteria as carriers for this genetic material 
confer ease of application, the ability to target immune inductive organs and cells and 
possess powerful adjuvant properties [97]. Most experience was collected by the use 
of different recombinant attenuated Salmonella strains, in animal models, in primates 
as well as clinical trials [123; 124; 182]. Such strains have been successfully used as 
carriers for DNA vaccines in immunization protocols against a variety of pathogens 
like bacteria, viruses, fungi and parasites, but also for protection or therapy of cancer 
(reviewed in [97]).  
Salmonella have not only been used for immunization, but also for gene therapy 
applications, e.g. to complement in vitro the monogenic defect in macrophages from 
patients with hereditary haemochromatosis by transferring the HFE gene [110]. 
Application of attenuated Salmonella carrying an expression plasmid for interferon γ 
(IFN-γ) to IFN-γ deficient mice rescued the mice from a lethal challenge with 
Salmonella [118]. Other examples for in vivo gene therapy mediated by Salmonella 
include transfer of CD40L, which protected the mice from a B cell lymphoma 
challenge [173], and transfer of the genes for interleukin-12 (IL-12) or granulocyte-
macrophage colony-stimulating factor (GM-CSF), both leading to the expression of 
the particular cytokine and suppression of tumour growth [187]. 
Recent developments in bacteria-mediated gene transfer involve the use of bacterial 
artificial chromosomes (BACs), as was shown by transfer of such large DNA 
fragments to HeLa cells by an invasive E. coli strain in vitro [113]. This system has 
virtually no size limitation for the transferred genetic material. Fragments of up to 1 
Mb can be carried. Furthermore, transfer of double stranded RNA from E. coli to 
various cells of the nematode C. elegans was shown, leading to target specific gene 
silencing by RNA interference [168; 169]. These findings impressively underline the 
potential of bacteria as carriers for therapeutic agents in a wide variety of 
applications, including vaccination against infectious diseases, complementation of 
monogenic defects and cancer gene therapy.  
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1.5 Cancer Gene Therapy  
Of all clinical gene therapy trials, 66% are addressing cancer 
(http://www.wiley.co.uk/genmed/clinical). Cancerous cells exhibit properties that 
distinguish them from normal, healthy cells of the body. These differences can be 
used to specifically direct treatment to abnormal cancer cells while leaving normal 
cells unaffected. Thereby adverse side effects are minimized.  
Development of tumours is associated with multiple alterations on the genetic level. 
Uncontrolled growth is supported for example due to mutations that result in over-
expression of proto-oncogenes or down-regulation of tumour-suppressor genes [39]. 
As long as these two gene groups are in balance with each other, cell proliferation 
and death is properly controlled. Disturbance of this balance leads to uncontrolled 
cell proliferation. More mutations are acquired during this process and the 
transformed cells become more and more malignant and heterogeneous with respect 
to each other. Therefore, effective treatment should address aspects that are 
common to all cancers. Several such strategies have been developed recently, 
including oncogene inactivation, tumour suppressor gene replacement, inhibition of 
angiogenesis, immunopotentiation and molecular chemotherapy [62]. Different 
systems have been used to realize these strategies. 
Oncogene inactivation: Targeted disruption of proto-oncogenes is one promising 
strategy for cancer gene therapy. These genes are important during fetal 
development to achieve sufficient amounts of cells in all organs, but most of them are 
silenced afterwards to prevent abnormal tissue growth. Inactivation of these genes 
can be achieved on different levels of gene expression: (1) inhibition of oncogene 
transcription into mRNA; (2) reduction of mRNA translation into protein; (3) 
interference with oncoprotein transportation and function [62]. Transcription of genes 
can be, for example, blocked by using DNA oligonucleotides that bind specifically to 
the promoter region of the gene of interest, forming triple helix structures that prevent 
the binding of the RNA polymerase complex and subsequently transcription into 
mRNA [35; 80-82; 92].  
A similar approach to reduce oncogene translation relies on the use of 
oligonucleotides that bind to mRNA in a complementary manner. The resulting 
double-stranded mRNA molecules are then degraded by intracellular enzymes. This 
approach has been used (in combination with chemotherapy) to block bcl-2 
10 
oncogene translation in prostate and breast cancer cells [99; 170]. However, the 
ability of these oligonucleotides to reduce translation is concentration dependent and 
therefore tumour cells often continue to produce low levels of oncogenes.  
Most recently, so called ribozymes have been developed, i.e. specialized RNA 
molecules that bind and cleave targeted mRNA sequences, thus preventing 
translation into protein. This technique has been employed to destroy over-expressed 
mRNAs in a variety of cancers [1; 8; 75; 156; 162; 167].  
To interfere with oncogenes on the protein level, intracellular single chain antibodies 
(“intrabodies”) have been used. After transfer of the coding sequence into the cancer 
cell, the intrabodies are expressed and bind to specific oncogenes, hence preventing 
the interaction of the oncoprotein with its target. Intrabodies have been developed 
against p53, erb2 and cyclin E proteins that are over-expressed in ovarian and breast 
cancers [3; 17; 160]. 
Replacement of tumour suppressor genes: the proteins encoded by tumour 
suppressor genes generally are involved in the cell cycle control and mediate DNA 
repair functions. Damage of DNA usually triggers cell cycle arrest and induces DNA 
repair mechanisms. If the damage cannot be corrected, the cell undergoes 
apoptosis. In case the expression of tumour suppressor genes is inhibited, cells with 
altered DNA sequences can continue to proliferate and propagate their mutations to 
daughter cells. Since DNA repair is not triggered by the defective tumour suppressor 
genes, the cells will acquire new mutations and at the same time avoid apoptosis. As 
consequence, they will become dedifferentiated with time. Several tumour 
suppressor genes have been shown to arrest growth and induce apoptosis when 
transfected into cancer cells, including p53, Rb and PTEN [11; 43; 45; 108; 145; 
151]. 
Inhibition of angiogenesis: one feature that is common to all solid tumours 
regardless of their origin is their dependence on adequate blood supply that meets 
the demands for nutrients and oxygen. As a logical consequence, gene therapies 
have been developed that interfere with angiogenesis and tumour adaptation to 
hypoxia. Gene transfer of angiostatin and endostatin, two potent natural inhibitors of 
angiogenesis, has led to decreased angiogenesis and reduced tumour growth in 
different models [16; 149; 161]. Anti-sense oligonucleotides against a subunit of αvβ3 
integrin diminished angiogenesis in transfected human endothelial cells [87]. The 
same technique was used to target hypoxia inducible factor-1 (HIF-1), a transcription 
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factor that is up-regulated by low oxygen concentrations and activates angiogenesis-
associated genes (e.g. vascular endothelial growth factor, VEGF). Clinically, over-
expression of the alpha subunit of HIF-1 correlates with treatment failure and 
mortality in a variety of human cancers. When mice were treated by antisense 
oligonucleotide gene therapy to HIF-1 alpha, down-regulation of VEGF, decreased 
microvessel density in tumours and rejection of small lymphomas were observed 
[161]. These results indicate that inhibition of angiogenesis might be a powerful tool 
in the therapy of solid cancers in general.  
Immunopotentation: one of the reasons why cancer cells can spread in the body 
without being attacked by the immune system is their escape from immune 
recognition, e.g. by downregulating MHC molecules. In this case, altered tumour 
associated proteins cannot be presented to cytotoxic or helper T cells. 
Immunopotentiation is the enhancement of the immune system’s ability to destroy 
cancer cells. One can distinguish between passive immunopotentiation, which 
involves boosting of the natural immune response, and active immunopotentiation, 
which requires the initiation of an immune response against a previously 
unrecognized tumour. Strategies for passive immunopotentiation include transfection 
of cytotoxic T cells, NK cells, macrophages and dendritic cells with genes encoding 
cytokines or growth factors ex vivo [125]. Also, immune stimulatory cells can be 
pulsed with RNA from tumour cells in order to enhance an immune response against 
specific antigens of the tumour [66]. Strategies for active immunotherapy include 
genetic modification of tumour cells, e.g. by introduction of genes encoding MHC 
molecules, the co-stimulatory molecule B7, or cytokines. These cells are then 
irradiated and reintroduced into the patient [152].  
Molecular chemotherapy: the principle of molecular chemotherapy or suicide gene 
therapy is based on the systemic administration of non-toxic pro-drugs that are 
turned into cytotoxic compounds only in previously transfected cancer cells. Into 
these cells genes are introduced that code for enzymes capable of converting the 
pro-drug into the active cytotoxic drug. Not only the directly modified cell is affected, 
since the toxin can be exported to neighbouring cells through gap junctions as soon 
as a certain level of the toxic compound is reached. Once the toxin reaches high 
enough levels, the originally transfected cell as well as the neighbouring cells die 
(bystander effect). Therefore, only a fraction of the cells in a solid tumour has to be 
transfected for successful suicide gene therapy.  
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A recent phase I study has shown that suicide gene therapy can be successfully and 
safely be used in humans. The authors used an adenoviral vector encoding both 
thymidine kinase of herpes simplex virus (HSV-TK) and cytosine deaminase (CD) 
from E. coli for therapy of locally recurrent prostate cancer [42].  
These results show that intensive research is carried out in the field of cancer gene 
therapy. All the strategies presented above heavily rely on the efficient transfer of 
genetic material to tumour or effector cells. Mostly, viral vectors are used for this kind 
of therapy, since they confer the most effective transfection. However, due to recent 
events [56] viral vectors are met with significant concerns regarding safety in 
humans. Therefore a variety of non-viral vectors have been tested. These suffer yet 
from too low transfection rates in vitro and especially in vivo. Thus, the ideal vector 
for cancer gene therapy still has to be developed.  
Intracellular bacteria have recently been shown to specifically target to and replicate 
in solid tumours [186]. This represents an exciting new possibility. Thus bacteria 
await to be explored in detail as vectors for targeted delivery of therapeutic genes to 
tumours.  
1.6 Bacteria in cancer treatment 
Several decades ago it was reported that some bacteria can take advantage of the 
growth conditions found in necrotic areas of solid tumours. Low oxygen concentration 
and high nutrient content led to exclusive or at least preferential proliferation of the 
microorganisms in tumour tissue. In the study of Malmgren and Flanigan [102], 
spores of the Gram-positive, obligate anaerobe bacterium Clostridium tetani were 
injected intravenously into tumour bearing mice. Although the spores were found 
throughout the body, only those that had entered the hypoxic regions of the tumour 
germinated and proliferated. Because of the particular pathogenic bacterium used, 
mice succumbed to tetanus poisoning 48 hrs after the infection, while control mice 
without a tumour, but infected with the same dose of spores, showed no signs of 
poisoning. Thereafter, several experiments involving different species of Clostridium 
were undertaken in mice and humans which led to the conclusion that growth of the 
microorganism in the tumour induces destruction of large parts of the malignant 
tissue (“oncolysis”). However, a viable, well oxygenated rim remained from which the 
tumour could re-establish itself. Nevertheless, these findings brought about the idea 
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to use bacteria as a vehicle to deliver anti-cancer agents selectively to tumour 
tissues.  
The main focus so far was on the delivery of pro-drug converting enzymes, either by 
using engineered strains producing the protein itself or by using bacteria carrying a 
eukaryotic expression plasmid encoding the enzyme. The latter approach requires 
plasmid transfer from the bacteria to the tumour cell. Thus a clone of Clostridium 
sporogenes was used that carried a plasmid with the Escherichia coli codA gene 
[96]. The codA gene codes for cytosine deaminase, an enzyme that converts the 
non-toxic pro-drug 5-fluorocytosine (5-FC) into the cytotoxic 5-fluorouracil (5-FU). 
Spores of the recombinant strain were used to colonize tumours in C3H/Km mice, 
and the effect of systemic administration of 5-FC was addressed. Significant anti-
tumour effects were observed that were at least equivalent to those observed after 
administration of the highest tolerated dose of the highly toxic chemotherapeutic 5-
FU.  
Other bacteria have also been reported to preferentially replicate in necrotic areas of 
solid tumours. When administered intraperitoneally into melanoma bearing C57/B6 
mice, an attenuated auxotrophic strain of Salmonella typhimurium showed an up to 
9000:1 ratio of the number of bacteria found in tumours to that found in liver. Tumour 
growth was suppressed and survival of the mice was prolonged already after 
treatment with the bacteria alone [126]. In addition, this strain was engineered to 
produce thymidine kinase of herpes simplex virus (HSV-TK). This enzyme 
phosphorylates the pro-drug ganciclovir (GCV). The resulting monophosphate form 
of GCV is subsequently converted by cytosolic enzymes into the triphosphate form, 
which intercalates into replicating DNA and leads to cell death. Application of this 
recombinant attenuated Salmonella strain and administration of GCV led to an even 
more pronounced tumour regression and survival of treated mice.  
One problem of administering high doses of Gram-negative bacteria is their potential 
to induce a TNF-α mediated toxic shock, which is mediated by Lipid A, a compound 
of the bacterial cell wall. The msbB gene of E. coli and Salmonella is involved in the 
synthesis of this lipid. The disruption of this gene in Salmonella reduced TNF-α 
induction and increased the LD50 of this bacterium 10.000-fold. Nevertheless, the 
capacity to target into the tumour and suppress its growth was retained [100]. 
Lately, a similar phenomenon was described for attenuated strains of Vibrio cholerea, 
an extracellular bacterium, and Listeria monocytogenes, as well as the laboratory 
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strain E. coli DH5α. Yu et al. showed that these bacteria accumulated in tumours of 
nude mice after intravenous injection [186]. However, these mice lack functional T 
cells and therefore are immuno-compromised. The V. cholerea strain was able to 
colonize tumours also in immunocompetent C57/B6 mice and Lewis rats [186].  
Alternative explanations for the selective accumulation of bacteria in tumours except 
special nutrients and low oxygen content in the tumour microenvironment have been 
proposed. One hypothesis is based on the finding that some bacteria tend to adhere 
to tumour cells but not to benign cells [34]. Another idea is that the impaired 
lymphatic system in tumours leads to reduced immunosurveillance, thereby 
protecting the bacteria from the immune system of the host [115].  
1.7 Bacteria as transfer vehicles for macromolecules 
Many bacteria species have been used as carriers for macromolecules into 
mammalian hosts. As mentioned above, these macromolecules comprise DNA [97], 
but also RNA [143; 168] and proteins [46; 48]. For vaccination purposes, 
heterologous expression of protein antigens in Salmonella, Shigella and Listeria has 
been shown to raise strong immune responses in the mouse. However, no success 
of this approach has been reported in humans. Regarding DNA transfer, Salmonella 
and Shigella have been mainly used for genetic vaccination, while Listeria were 
predominantly used for the transfer of complementing genes. In the present work, the 
potential of bacteria-mediated gene transfer for tumour therapy should be tested. 
Because of their broad host cell tropism and their ability to spread from cell to cell, 
Listeria and Shigella were employed for this purpose. Thus, these two bacterial 
carriers are described in more detail below.  
1.7.1 Listeria monocytogenes 
Listeria monocytogenes is a rod shaped Gram-positive, facultative anaerobic 
intracellular bacterium. It is motile at temperatures between 10 and 25°C, does not 
form spores and has no capsule. It is almost ubiquitously found in the environment, 
e.g. in soil, water, a large number of foods and faeces of humans and animals. L. 
monocytogenes can infect humans and a wide variety of other vertebrates. The 
disease caused by this bacterium is known as listeriosis, whose characteristic 
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features are sepsis, meningitis and encephalitis [40; 53; 144]. In healthy individuals, 
L. monocytogenes shows little virulence and infections are rapidly cleared by the 
host’s immune system. If an infection can be established in a healthy person, it does 
in most cases not cause severe illness, but might be accompanied with flu-like 
symptoms and diarrhoea [53]. However, in newborns, elderly people or immune 
suppressed patients, the infection can be life threatening. Pregnant women are 
especially at risk, because the bacterium can cross the placental barrier [176] and 
infect the foetus, which in turn can lead to abortion, still birth or neonatal death. The 
microorganism is often taken up by contaminated food, like cheese and other milk 
products or smoked fish. It is able to survive high salt content and low pH values, and 
can proliferate at refrigerating temperatures, thereby representing a major problem in 
the safety of food processing.  
Intracellular life cycle 
Listeria monocytogenes is an invasive pathogen that can, besides phagocytic cells, 
enter several non-phagocytic cell types. The key features of its intracellular life cycle 
are summarized in Fig. 1.3. The cycle starts with the adhesion of the bacterium to the 
membrane of the eukaryotic host cell. The main bacterial factors involved in this step 
are internalin A (InlA) and internalin B (InlB) [21; 67]. InlA binds specifically to E-
cadherin, with a stringency that was unexpected. While InlA is effectively interacting 
with human E-cadherin, it cannot interact with the mouse homolog of this protein, a 
difference that is due to a single amino acid exchange at position 16 of the 
polypeptide [93].  
InlB, in contrast, has no such restricted host cell tropism and allows entry into a wide 
variety of cells [13; 67; 119]. gC1qR was identified as one of the receptors for InlB 
[12]. It is a surface protein that does not exhibit any features of a transmembrane or 
GPI-anchored protein, suggesting that this protein is interacting with another 
molecule to mediate the signals necessary for the rearrangement of the cytoskeleton 
involved in entry. Another receptor for InlB is the Met receptor tyrosine kinase, the 
receptor for hepatocyte growth factor. Interaction of InlB and Met leads to tyrosine 
phosphorylation of Met and the adapters Gab1 and Cbl, leading to L. monocytogenes 
invasion [148].  
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Fig. 1.3: Schematic view of the intracellular life cycle of L. monocytogenes. The different steps and the 
virulence factors involved are shown. See text for detailed explanation. 
 
This interaction with the host cell membrane leads to rearrangements of the actin 
cytoskeleton and engulfment of the bacterium by a zipper-like mechanism. 
Subsequently, the bacterium is taken up into the cell in a phagocytic vacuole. The 
membrane of this vacuole is disrupted shortly after uptake by Listeriolysin O (LLO), in 
synergy with phospholipase C B (plcB). Strains expressing LLO variants that display 
less lytic activity are also less virulent. Once in the cytosol, the bacteria multiply with 
a doubling time of approximately 1 hour.  
L. monocytogenes is able to move around in the cell by the recruitment of host cell 
actin; the key mediator of this intracellular movement is ActA, which is expressed on 
the bacterial surface in a polar fashion. In concert with several host cell proteins, an 
actin tail is assembled that propels the bacterium through the cytosol [20]. When the 
bacterium reaches the cell membrane, protrusions are formed, and the bacterium 
can be taken up by a neighbouring cell (“cell-to-cell spread”), resulting in the 
formation of a double membrane vacuole. This membrane can again be disrupted, a 
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process that is dependent on LLO and plcB but also requires phospholipase C A 
(plcA) [14]. The bacterium can then replicate in the cytosol of the new host cell and 
start a new infection cycle.  
 
 
 
Fig. 1.4: Organization of the L. monocytogenes virulence gene cluster (LIPI-1). Genes belonging to 
LIPI-1 are in grey. Dotted lines above the LIPI-1 genes indicate known transcripts [175].  
 
 
The virulence factors essential for this life cycle are regulated by prfA. The prfA, hly, 
actA, plcA and plcB genes are located in a virulence gene cluster (LIPI-1) on the 
bacterial chromosome (Fig. 1.4), while inlA and inlB are found in a distinct location, 
the so called internalin islet [175]. 
The course of a Listeria monocytogenes infection 
Since contaminated food is the major source for L. monocytogenes infection, the 
gastrointestinal tract is thought to be the primary site of entry into the host [176]. 
Before reaching the intestine, the bacteria have to cross the adverse environment of 
the stomach. During this step, a significant number of bacteria may be already killed. 
Once in the intestine, the Listeria cross the intestinal barrier by a mechanism that is 
still controversially discussed. Data are available that suggest invasion of intestinal 
epithelial cells from the apical side [79; 132]. Other studies suggest that entry occurs 
via the highly phagocytic M cells overlaying the Peyer’s Patches [74; 150]. Intestinal 
translocation of Listeria occurs without severe lesions in the gut of mice [103], 
suggesting that a phase of replication in the intestinal epithelium is not necessary for 
systemic infection. Indeed, the bacteria are translocated to deeper organs very 
rapidly. By using mutant strains lacking virulence factors like internalin A and B, LLO 
or ActA, or even the non-pathogenic species L. inocua it could be shown that 
translocation occurred at the same rate as with wild type Listeria monocytogenes 
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[130]. These findings favour the view that listerial translocation is a passive, non-
specific process [176].  
After crossing the intestinal barrier, the Listeria migrate rapidly via the lymph or blood 
to the mesenteric lymph nodes, the spleen and the liver [103; 130]. Experimental 
infections of mice via the intravenous route demonstrated that L. monocytogenes is 
rapidly cleared from the blood stream and taken up by resident macrophages in the 
spleen and liver [18; 23; 101]. Most of the bacterial load accumulates in the liver, 
presumably captured by Kupffer cells that line the hepatic sinusoids. Within the first 6 
hrs of infection, most bacteria in the liver are killed by neutrophilic granulocytes [106]. 
The remaining bacteria start growing and proliferate in mouse organs for 2 – 5 days.  
Listeria infection of hepatocytes, both in vitro and in vivo, results in apoptosis of these 
cells and the release of neutrophil chemotractants [135]. Neutrophils appear at the 
site of infection within the first 24 hrs, and their key role during Listeria infection was 
demonstrated by using monoclonal antibodies to deplete such cells [19; 24; 25; 133; 
136]. Mice depleted in neutrophils succumbed to an early, lethal infection, with large 
numbers of bacteria found in the liver parenchyma. Neutrophils migrating to the liver 
remove apoptotic hepatocytes and destroy released bacteria.  
The interaction between the Listeria, macrophages and neutrophils is critical for the 
host during the early phase of infection. Listeria infected macrophages produce TNF-
α and IL-12, which synergize to cause IFN-γ secretion by NK cells. In turn, IFN-
γ together with TNF-α leads to full activation of macrophages which then display 
increased levels of MHC class II molecules and become listericidal through the 
production of free radicals [4; 6]. The necessity of IFN-γ, TNF-α and IL-12 was shown 
by depletion experiments with monoclonal antibodies or the study of infections in 
appropriate knock out mice. Mice lacking any one of these cytokines quickly 
succumbed to a high dose infection (reviewed in [171; 172]).  
The adaptive immune response to Listeria infection is dependent on T lymphocytes. 
Since the bacteria are found in the cytosol as well as the phagosomes of professional 
antigen-presenting cells, the listerial antigens are presented via the MHC class I and 
class II pathway. Therefore, both specific CD4 and CD8 T cells are induced during 
Listeria infection. Especially cytotoxic T cells are important for sterile clearance of the 
bacteria and provide a memory pool of T cells capable of a more rapid immune 
response upon a secondary infection [91; 101; 104].  
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Most studies concerned with the immunity to Listeria focused on the obvious role of T 
cells in the immune response against this intracellular pathogen. However, there are 
additional plasma-protein dependent mechanisms that are involved in protection 
against this intracellular pathogen: 1) opsonization of the bacterium in the 
extracellular space by complement activation, leading to increased phagocytosis; 2) 
antibody binding to key surface molecules, inhibiting entry into host cells; 3) antibody 
mediated neutralization of toxins produced by the pathogen in the extracellular 
environment; 4) activity of antibodies inside of pathogen containing phagocytes, e. g. 
in the phagosome (summarized in [37]).  
Two studies have revealed a role for natural antibodies [114] and anti-LLO antibodies 
[36], respectively, in the context of Listeria infection. The first study showed that 
naïve C57/B6 mice have low but detectable levels of natural anti-Listeria IgM 
antibodies in their serum. Comparison of the early dissemination of bacteria in wild 
type C57/B6 mice and antibody lacking µMT mice after a high dose intravenous 
infection revealed 5-10 fold higher bacterial titres in liver, kidney and brain of mice 
lacking antibodies. In contrast, the bacterial titre in the spleen was 79-fold lower in 
these µMT mice as compared to wild type mice. The authors suggest that the 
microorganisms agglutinated by natural IgM were targeted to spleen macrophages 
due to their increased size. These results were obtained at 6 hrs post infection. Thus, 
it is not yet clear whether the observed differences have an influence on resistance at 
later time points of infection.  
In the second study the authors used anti-LLO antibodies to treat mice before 
intraperitoneal infection with Listeria. This resulted in lower numbers of bacteria in the 
spleen and liver both at 6 hrs and two days post infection. Furthermore, increased 
survival after a lethal challenge was demonstrated. As described above, the reasons 
for this effect could be opsonization of the bacteria due to surface associated LLO or 
inactivation of the toxin outside the cell or even inside the phagocytic vacuole. The 
relevance of these findings for natural infection might be questioned, though, since 
extremely low LLO specific antibodies are found in mice, even after several rounds of 
infection [36], and the intracellular replication and cell-to-cell spread protect the 
bacteria from the humoral immune response of the host. In contrast, titres of 
antibodies against LLO and other Listeria specific antigens were high in Listeriosis 
patients and healthy persons that were exposed to Listeria, indicating a potential role 
for the humoral immune response against Listeria in humans [54]. 
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Listeria monocytogenes mediated gene transfer 
L. monocytogenes mediated gene transfer in vitro has been shown for a broad range 
of host cells, including cell lines of epithelial origin, murine primary macrophages and 
macrophage-like cell lines, as well as human dendritic cells [30; 31; 55; 60; 88; 122]. 
To initiate gene transfer from the bacteria to the host cell, lysis of the bacterium has 
to be induced. This is currently achieved by two different systems. The first system is 
based on an attenuated strain of L. monocytogenes which lacks the actA, plcB and 
mpl genes [59]. This strain escapes efficiently from the phagosome, but is unable to 
move inside the cell or to spread from cell to cell. Its attractive property is that it 
causes less inflammatory reactions in vivo than the wild type strain. This attenuated 
strain was equipped with a bacteriophage derived autolysin expressed under the 
control of the actA promoter that is only active in the cytosol of host cells. With these 
bacteria, different genes were transferred into murine macrophages and primary 
human dendritic cells [29; 47; 158]. In vivo, gene delivery was shown in a study 
where cotton rats were injected intraperitoneally with L. monocytogenes carrying a 
eukaryotic expression plasmid encoding GFP. Reporter gene expression was 
detected in a limited number of peritoneal macrophages 3 days after infection [158]. 
An alternative system has been established in our group, employing antibiotics to kill 
intracellular bacteria and to initiate gene transfer (Fig. 1.5) [60]. It employs wild type 
L. monocytogenes or L. monocytogenes hly W491A – a strain that produces a LLO 
variant that possesses only ~10% lytic activity compared to the wild type LLO – as 
carriers for eukaryotic expression plasmids. Attenuation of the LLO activity 
significantly enhanced transfection efficiencies [88].  
After testing several different antibiotics and their effect on gene transfer, it was 
observed that a combination of penicillin and streptomycin was most efficient [88], 
indicating a mechanism for plasmid release that is dependent on the efficient lysis of 
the bacterial cell wall. Using this system, we could demonstrate transfer of different 
reporter genes to a variety of cell lines, and the functional transfer of the cftr cDNA 
and a cDNA encoding a fusion protein of CFTR and GFP to CHO-K1 and HEp-2 cells 
[88; 188].  
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Fig. 1.5: Schematic illustration of the in vitro gene transfer system used in this work. After infection, 
extracellular bacteria are killed by addition of gentamicin. Subsequently, intracellular bacteria are 
allowed to replicate and spread to neighbouring cells. Then, intracellular bacteria are lysed by addition 
of penicillin/ streptomycin. Upon lysis, the expression plasmids are released and transgene expression 
(exemplarily shown here for GFP) can be analyzed. 
 
In a recent study a vector/ carrier combination was presented in which the plasmid is 
stabilized in an antibiotic-free manner by a balanced suicide system [178]. The 
authors constructed a strain that lacks the essential gene encoding D-alanine 
racemase, and used a plasmid which complemented the D-alanine racemase 
mutation and carried a reporter gene. The possibility to stabilize the plasmid without 
an antibiotic resistance gene further adds to the safety of L. monocytogenes as a 
DNA carrier. 
So far, no significant in vivo transfer of genes using any of these Listeria-based 
systems has been observed, although specific immune responses against 
Mycobacterium tuberculosis were reported after vaccination of C57/B6 mice with a 
recombinant L. monocytogenes strain carrying an expression plasmid for 
mycobacterial antigens [107]. Therefore, systems based on L. monocytogenes as a 
carrier for gene transfer require further improvement. 
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1.7.2 Shigella flexneri 
As an alternative to Listeria, Shigella might be used for gene transfer, since these 
bacteria share properties with Listeria, like the ability to escape from the phagosome 
or to spread from cell to cell. The genus Shigella is a group of Gram-negative, 
facultative anaerobic bacteria that are genetically closely related to the genus 
Escherichia. The Shigella genus comprises the four species S. flexneri, S. boydii, S. 
sonnei and S. dysenteriae, which are further divided into serotypes according to 
biochemical differences and variations of their O-antigen. Shigella flexneri is divided 
into 13 different serotypes. It causes an infectious disease known as shigellosis by 
invading the colonic and rectal epithelium of primates and humans. The resulting 
acute mucosal inflammation causes severe tissue damage and leads to the clinical 
symptoms of watery diarrhoea, severe abdominal pain and cramping, and eventually 
bloody mucoid stool. Approximately 165 million people suffer from shigellosis each 
year, 1.1 million cases resulting in death. The vast majority of these cases occur in 
developing countries, and 69% of all patients are children under the age of five [73]. 
Transmission of the pathogen usually takes place via the faecal-oral route, which is 
augmented by poor hygienic conditions and close personal contact in developing 
countries. Mice are naturally not infected by this bacterium.  
Intracellular life cycle 
Shigella preferentially enters epithelial cells via their basolateral membrane [111]. 
However, the exact reason for that remains unclear. The mucin layer of colonic 
epithelial cells might act as a physical barrier and prevent close contact of the 
bacteria to the host cell, which is important for Shigella entry into epithelial cells. On 
the other hand, the basolateral membrane might display molecules that are not 
present on the apical side of the cell but are used as receptors for the Mxi/Spa 
secretion system. Close contact of this bacterial component to the host cell is 
essential for the induction of the first steps of the invasion process. Interactions 
between Shigella components and basolateral membrane proteins have been shown, 
including binding of Ipa proteins (see below) to α5β1 integrin [179] and binding of 
IpaB to CD44 [155]. Both α5β1 integrin and CD44 can act as cytoskeleton linkers, 
suggesting that they might take part in the reorganization of the actin skeleton 
(“membrane ruffling”) seen during uptake of Shigella. It also has been shown that 
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adhesion of Shigella to epithelial cells is dependent on the length and presence of 
the O-antigen [85]. These results suggest a potential involvement of LPS receptors 
like CD14 or Toll-like receptors (TLRs) in the entry process, both of which are found 
on the basolateral membrane of epithelial cells [2; 65].  
The actual uptake of the bacterium by the cell occurs in a macropinocytotic process, 
where S. flexneri induced rearrangements of the host cell cytoskeleton engulf the 
bacterium and form a vacuole. Two loci on the 220 kb virulence plasmid of S. flexneri 
are crucial for this process, the ipa locus and the mxi-spa locus. The ipa locus 
encodes the proteins IpaA, IpaB, IpaC and IpaD, which are the effector molecules of 
bacterial entry into the host cell. These proteins are secreted by the type-III secretion 
system encoded by the mxi-spa locus.  
The detailed mechanisms by which Ipa proteins trigger uptake of the bacterium are 
not completely understood. Secretion of the Ipa proteins is induced by contact with 
the host cell [105; 117]. Subsequently, the N-terminus of IpaC binds IpaB, leading to 
the insertion of the two hydrophobic proteins into the host cell membrane to form a 
pore [10; 57]. Other effector proteins are also thought to access the host cell 
cytoplasm via this pore. Several of the Ipa proteins can then interact with 
cytoskeleton associated proteins, leading to rearrangements of the actin filaments, 
formation of membrane extensions and eventually internalization of S. flexneri within 
a macropinocytic vacuole.  
This vacuole is rapidly lysed by IpaB, which acts as membranolytic toxin, leading to 
the release of Shigella into the host cell cytosol [61]. IpaC may also be involved in 
this lytic process by inserting its hydrophobic regions into the membrane [28; 89]. 
Once in the cytosol, Shigella can replicate with an in vitro doubling time of 40 
minutes.  
mxiE, a gene located in the mxi/spa locus, is a transcriptional regulator of several 
putative virulence factors and is up-regulated only in the cytosol of the host cell. This 
suggests a role for mxiE as a general regulator for virulence genes involved in the 
post-invasion steps of infection [78].  
S. flexneri, like L. monocytogenes, is able to recruit the host cell’s actin to move 
around in the cell and also spread to neighbouring cells. The outer membrane protein 
IcsA is expressed on one pole of the bacterium and mediates actin recruitment [51]. 
DegP also seems to be required for efficient intracellular spread and unipolar 
expression of IcsA, although its exact function is still unknown [131]. IcsA interacts 
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specifically with neural Wiskott-Aldrich syndrome protein (N-WASP) and possibly with 
vinculin [50; 98; 163; 166], thus stimulating actin polymerization mediated by the 
actin-related protein (Arp) 2/3 complex [38; 164]. This actin polymerization propels 
the bacterium through the cytosol of the host cell. 
When the moving bacterium reaches the cell membrane, a protrusion is formed 
which is actively taken up by the neighbouring cell [109]. The new double membrane 
vacuole is lysed by secreted IpaB and IpaC [116]. Another protein, VacJ, has been 
shown to be also essential for releasing Shigella into cytoplasm of the “secondary” 
cell [165]. Here, S. flexneri can replicate again and start a new infection cycle. In that 
way, it can move within the intestinal epithelial layer without being exposed directly to 
the humoral effector molecules of the immune system of the host.  
The course of a Shigella flexneri infection 
S. flexneri is highly infectious, and as little as 100 bacteria can cause disease in adult 
humans [33]. During uptake via the oral route, Shigella can survive the acidity of the 
stomach by up-regulating acid resistance genes. Once in the intestine, Shigella 
flexneri is taken up by highly phagocytic M cells that are concentrated in the 
epithelium above the mucosa-associated lymphoid tissues (reviewed in Fig. 1.6), but 
are also found all over the small intestine. These cells sample antigen from the lumen 
of the gut and pass it to the basolateral side of the epithelium by transcytosis, where 
lymphocytes and macrophages reside to take up antigen and raise a mucosal 
immune response. By this mechanism, S. flexneri crosses the epithelial barrier and 
gains access to macrophages and the basolateral membrane of epithelial cells. 
Furthermore, S. flexneri has recently been shown to be able to cross a model 
intestinal barrier by interfering with tight junction associated proteins of human 
intestinal epithelial cells, thereby using an M cell independent way of entry (Fig. 1.6; 
[138]).  
Once entered, the bacteria replicate inside the cells and spread to neighbouring cells 
(as described above). As Shigella infection proceeds, infected macrophages undergo 
apoptosis, which leads to production of high amounts of interleukin-1 (IL-1). IL-1 is 
important in induction of inflammation and recruits polymorphonuclear cells (PMN) 
cells to the site of infection. Furthermore, IL-8 is induced by infection of epithelial 
cells, again attracting PMN cells. Consequently, the integrity of the epithelial lining is 
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disrupted to allow the PMN cells to transmigrate to the luminal side, at the same time 
facilitating entry of luminal bacteria through the epithelial barrier (Fig. 1.6). The 
recruitment of PMN cells is crucial for the generation of shigellosis-associated 
inflammation and tissue damage, as was shown in studies by inhibiting either IL-1 or 
IL-8 in rabbits [140; 141]. 
When CD18, an adhesion molecule used by PMN cells during migration, was 
blocked, tissue damage and bacterial invasion was diminished [127]. It is somehow 
stunning that the same PMN cells promote the local spread of the bacteria by 
disrupting the epithelial layer and at the same time also restrict the infection to the 
submucosa and prevent systemic dissemination. 
The inflammation can persist in the gut for over a month. Resident macrophages and 
infiltrating monocytes are unable to efficiently kill the bacteria in their phagosomes 
but instead undergo apoptosis that leads to the expression of IL-18 [58; 191]. This 
cytokine induces the secretion of IFN-γ by NK cells and T cells [9] which in turn 
activates more macrophages and fibroblasts, possibly inhibits bacterial replication 
within epithelial cells and finally promotes bacterial clearance [180]. Only invading 
PMN cells are capable of killing Shigella in their phagosomes and play a crucial role 
in controlling the infection.  
 
 
Fig. 1.6: Illustration of S. flexneri infection of the intestine and intracellular life cycle (from [73]). See 
text for more details. 
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Very little is known about the cellular immune response to S. flexneri. T cell activation 
was observed in shigellosis patients, and cytokines induced by vaccination against S. 
flexneri suggest Th1 and Th2 responses [68-70; 86; 174; 190]. Other studies 
conducted in a mouse model defective of T cells did not support the view that T cell 
responses are essential for protection against S. flexneri [181].  
More data are available for the humoral immune response against Shigella infection 
from serological studies in infected humans and from animal experiments. These 
data suggest a crucial role for humoral responses in protective immunity. As serum 
IgG, IgM and secretory IgA have all been detected in infected individuals it seems 
that both systemic and mucosal immunity is activated. The main specificities of the 
antibodies are directed against serotype specific LPS and some virulence plasmid 
encoded proteins, including the Ipa proteins. The overall importance of an antibody 
response has recently been shown by a study which showed that a reduced and 
delayed antibody response in children compared to adult patients is the likely cause 
for increased susceptibility of infants to Shigella infection [134].  
Shigella flexneri mediated gene transfer 
S. flexneri is known to infect intestinal epithelial cells and macrophages in humans 
after oral uptake. However, as mentioned above, this pathogen is not invasive in the 
murine intestine, therefore limiting the experimental evaluation of this carrier to nasal 
challenge models. S. flexneri has so far been used mainly as DNA carrier in 
vaccination protocols against viral antigens. The first studies were undertaken with 
an attenuated strain of S. flexneri bearing a mutation in the asd gene, which encodes 
an essential compound for cell wall synthesis, as described before. These bacteria 
were shown to be able to deliver a eukaryotic expression plasmid encoding E. coli β-
galactosidase to mammalian cells [153]. Also, humoral and cellular immune 
responses against β-galactosidase were raised after nasal inoculation of mice with 
these bacteria [154]. 
Intranasal immunization of mice with Shigella harbouring an expression plasmid 
encoding for HIV gp120 induced specific T cell responses and protected the mice 
against a challenge with a recombinant vaccinia virus [146]. When strains of Shigella, 
S. typhimurium and S. typhi carrying expression plasmids for viral antigens were 
directly compared by intranasal application, the Shigella strain proved to be superior 
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for the induction of antigen-specific CD8 T cell responses. Intramuscular injection of 
DNA showed similar cellular responses as the Shigella strain [177]. Regarding the 
humoral immune response, the DNA vaccine induced strong, specific IgG response 
in serum, compared to a superior mucosal antigen-specific IgA response induced by 
the Shigella vector. Other Shigella strains were used in combined prime-boost 
immunization protocols against HIV antigens together with naked DNA or viral 
vectors [146; 185]. Shigella were also used to deliver DNA vaccines encoding 
measles virus (MV) proteins to mice and cotton rats, leading to antigen-specific 
cellular responses and low levels of antibodies in serum [41; 123]. Thus, despite of 
the limits in model organisms S. flexneri appears to be an efficient vector for gene 
transfer in vivo. 
In this work, Shigella flexneri is used not as carrier for DNA vaccines, but its ability to 
transfer DNA to tumour cells of epithelial origin is explored.  
1.8 Aim of this work 
Gene therapy is a powerful approach to cure or interfere with a wide range of 
diseases, including monogenic disorders, infectious diseases and cancer. However, 
in many cases the efficiency of gene transfer as well as the level and duration of 
expression were too low for clinical benefits, indicating the necessity for further 
improvement of the vectors and gene transfer systems used. Therefore, bacteria 
were introduced as alternatives to the vector systems used so far.  
A L. monocytogenes-based in vitro gene transfer system that involves antibiotic-
mediated killing of intracellular bacteria has been established and optimized by our 
group. In previous studies, this system allowed successful transfer of reporter genes 
as well as the functional transfer of a potentially therapeutic gene, cftr, to mammalian 
cells [88]. For the in vivo application of this transfer system, however, several 
obstacles have to be overcome, the most important one being efficiency of 
transfection.  
In the first part of this work, therefore, the mechanism of “bacteriofection” was 
investigated in more detail. By identifying and eliminating the restrictions of this 
approach the transfer efficiencies should be significantly enhanced. Also, the fate of 
potentially co-transferred bacterial chromosomal DNA should be clarified, a safety 
issue that needed to be addressed.  
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In the second part, the use of bacteria as carriers for cancer gene therapy should be 
evaluated, using two different species, Listeria monocytogenes and Shigella flexneri. 
Our in vitro gene transfer system had to be adapted to the use of S. flexneri 
attenuated strains, and gene transfer to tumour cell lines in vitro by S. flexneri and L. 
monocytogenes needed to be demonstrated. Subsequently, a mouse tumour model 
should be employed to investigate the fate of the bacteria after infection via the 
intratumoural, intravenous and/ or intraperitoneal route. Finally, bacteria-mediated 
gene transfer to tumour tissue in vivo should be analyzed using different reporter 
genes.  
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2 Materials and Methods 
2.1 Bacterial strains and growth conditions 
The Escherichia coli (E. coli) strains TOP 10 and DH5α (Invitrogen, Groningen, The 
Netherlands) were used for general cloning. E. coli were grown in Luria Bertani (LB) 
broth or on LB-agar plates [139] at 37°C. Ampicillin (Sigma, Taufkirchen, Germany) 
was added at 100 µg/ ml kanamycin at 30 µg/ ml or erythromycin (Sigma) at 400 µg/ 
ml when required. L. monocytogenes strains EGDe [94] and hlyW491A [88] were 
grown in Brain Heart Infusion (BHI) broth or on BHI-agar plates (Difco, Detroit, MI) at 
37°C. Medium was supplemented with 5 µg/ml erythromycin when indicated. Minimal 
medium for growth of L. monocytogenes W491A was freshly prepared and 
composed of the following [129]: 
 
Compound Weight/ litre 
KH2PO4 6.56 g 
Na2HPO4*7H2O 30.96 g 
MgSO4*7H2O 0.41 g 
Ferric citrate 0.088 g 
Glucose 10 g 
L-Leucine 0.1 g 
L-Isoleucine 0.1 g 
L-Valine 0.1 g 
L-Methionine 0.1 g 
L-Arginine 0.1 g 
L-Cysteine 0.1 g 
L-Glutamine 0.6 g 
Riboflavine 5 mg 
Thiamine 1 mg 
Biotin 0.5 mg 
Thioctic acid 5 µg 
 
S. flexneri strains ∆aroD and ∆dap were grown in Tryptic Soy Broth (TSB) or on TSB-
agar plates (Becton Dickinson, Heidelberg, Germany) supplemented with 200 µM 
congo red (Serva, Heidelberg, Germany) at 37°C. Medium for S. flexneri ∆dap was 
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additionally supplemented with 100 µg/ ml DAP (Fluka, Buchs, Switzerland) and 
30 µg/ ml kanamycin. Ampicillin was added at 50 µg/ ml when indicated.  
Transformation of bacteria has been described elsewhere [120; 139]. 
2.2 Expression plasmids 
 
 
 
 
Fig. 2.1: Plasmid map of pERL3-T7-IRES-GFP. GFP expression is driven by the T7 promoter and an 
IRES element to provide cytosolic expression in host cells in the presence of T7 RNA polymerase. 
See text for construction details. 
 
 
pERL3-T7-IRES-GFP 
The IRES containing fragment from plasmid pMC-1 [32] was isolated by NotI 
digestion followed by Klenow treatment to generate blunt ends, and subsequent 
digestion with EcoRI. The vector pBluescript II KS(+) (Stratagene, La Jolla, CA) was 
treated in the same way, and the two fragments were ligated, resulting in the plasmid 
pBS-IRES. As the T7 promoter an adaptor fragment was used consisting of the 
oligonucleotides AAT TTC CCT ATA GTG AGT CGT ATT AG (EcoRI-pT7-SalI-V) 
and TCG ACT AAT ACG ACT CAC TAT AGG GA (EcoRI-pT7-SalI-R) that contained 
ends compatible with SalI and EcoRI. The sequence was designed such that the 
EcoRI site was destroyed upon ligation. This fragment was ligated into the 
corresponding restriction sites of pBS-IRES, giving rise to the plasmid pBS-T7-IRES. 
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The coding sequence of EGFP was obtained from pEGFP-1 (Clontech) by digestion 
with the enzymes SalI and Bsp120I and was inserted into the SalI and NotI sites of 
pBS-T7-IRES resulting in the plasmid pT7-IRES-GFP. The NotI restriction site was 
then destroyed by treatment with Klenow and a XhoI site was introduced using the 
linker CCCTCGAGGG. Then the T7 promoter controlled expression cassette was 
isolated by digestion with XhoI and PstI and ligated into the XhoI and PstI sites of the 
plasmid pERL-3 [60]. By this step, the kanamycin resistance gene was destroyed. 
The final plasmid was named pERL3-T7-IRES-GFP. 
 
 
 
 
Fig. 2.2: Plasmid map of pERL3-CMV-DsRed2. This plasmid can be replicated in E. coli as well as in 
L. monocytogenes via the pBR or pAMβ1 ori, respectively. Expression of the red fluorescent protein 
DsRed2 is driven by the eukaryotic CMV promoter. See text for construction details. 
 
 
pERL3-CMVDsRed2 
The coding sequence DsRed2 was obtained by restriction digestion of the plasmid 
pDsRed2-N1 (Clontech) with XmaI and NotI. The coding sequence of EGFP was 
removed from the plasmid pERL3-CMVGFP [60] by digestion with the same 
enzymes and the DsRed2 containing fragment was ligated into these sites. 
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Fig. 2.3: Plasmid map of pERL3-CMV-GFP. This plasmid is equivalent to pERL3-CMV-DsRed2, but 
carries GFP as reporter gene. The construction of this plasmid has been described elsewhere [60]. 
 
 
 
 
Fig. 2.4: Plasmid map of pCMV-GFP. β-galactosidase was removed from pCMV-β (Clontech) by 
digestion with NotI. GFP was obtained from pEGFP-1 (Clontech) by digestion with NotI and Bsp120I 
and the two fragments were ligated. 
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Fig. 2.5: Plasmid map of pCMV-luc-m2A. This plasmid confers expression of the firefly luciferase 
gene via the eukaryotic CMV promoter. The luciferase gene was isolated from pGL-3 Basic (Promega) 
and cloned into pCMVβ-m2A [5] via SmaI and SalI.  
2.3 Cell lines 
BHK-21 (ATCC CCL-10), TS/A [112], CT26 (ATCC CRL-2638), CHO-K1 cells (ATCC 
CCL-61) and HEp-2 cells (ATCC CCL-23) were cultured in IMDM (Gibco BRL, 
Eggenstein, Germany) supplemented with 10% heat-inactivated FCS (Integro, 
Zaandam, The Netherlands) and 0.25 mM β-mercaptoethanol (Serva, Heidelberg, 
Germany). The cell line ST31-7 [88] was grown in the same medium but containing 
additional G418 (1 mg/ml; Gibco BRL). Cells were cultured at 37°C and 5% CO2 in a 
humidified atmosphere. 
The clones CHO-GFPCFTR+.1 and .2 stably expressing GFP-CFTR were generated 
by transfecting the plasmid pERL3-CMVGFPCFTR-neo into CHO-K1 cells using the 
method of calcium phosphate precipitation [139]. CHO-K1 transfectants were 
selected by growth in medium supplemented with G418 (1 mg/ml; Gibco BRL) and 
were cloned by sorting of single, GFP-positive cells using a FACSVantage (Becton 
Dickinson, Heidelberg, Germany) and screened by fluorescence microscopy.  
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2.4 L. monocytogenes- and S. flexneri-mediated transfer of euka-
ryotic expression plasmids to mammalian cells 
Cells were seeded 24 hrs before infection in 24-well plates at a density of 5x104 
cells/ well, resulting in approximately 1x105 cells/ well at the time of infection. 
Overnight cultures of L. monocytogenes and S. flexneri strains were diluted 1:50 in 
the corresponding medium and grown for 3-4 hrs and 2.5 hrs, respectively. When 
grown in minimal medium, L. monocytogenes from an overnight culture were washed 
twice with minimal medium, diluted 1:50 in minimal medium and incubated for 14 hrs. 
After washing once with PBS, bacteria were added to cell cultures at the indicated 
multiplicity of infection (MOI) and in a total volume of 200 µl medium. For S. flexneri 
∆dap, PBS and culture medium was supplemented with 100 µg/ ml DAP. 
Subsequently, infection cultures were centrifuged to enhance invasion and incubated 
for 1.5 -2 hrs at 37°C. Cells were then washed twice with PBS and cultured in 
medium supplemented with 50 µg/ml gentamicin to kill the remaining extracellular 
bacteria. In case of Listeria, after additional 4 hrs of incubation at 37°C, intracellular 
bacteria were lysed by exchanging the gentamicin-containing medium for fresh 
medium supplemented with penicillin G (100 U/ ml) and streptomycin (100 µg/ ml) 
(Cytogen, Ober-Mörlen, Germany). Cells were incubated for the indicated time 
periods at 37°C and finally transient transgene expression was analyzed or cells 
were processed for electron microscopy or DNA isolation. 
To detect GFP or DsRed expression by fluorescence microscopy, cells grown on 
coverslips were fixed with 3.7% formaldehyde in PBS for 20 min at room 
temperature. Coverslips were mounted in Fluoprep (bioMérieux, Marcy l’Etoile, 
France) and preparations examined by epifluorescence microscopy using an Axiovert 
135 TV microscope (Zeiss, Oberkochen, Germany) equipped with a Plan-
Apochromat 100x/1.40 NA oil immersion objective. Images were recorded with a 
cooled, back-illuminated CCD camera (TE/CCD-1000 TKB; Princeton Instruments, 
Trenton, NJ). Flow cytometry for quantitation of GFP- or DsRed-expressing cells was 
performed with trypsinized, unfixed cells using a FACSCalibur (Becton Dickinson, 
Heidelberg, Germany) and CellQuest software (Becton Dickinson). The Dual Glo 
luciferase assay system (Promega, Mannheim, Germany) was used for analysis of 
luciferase expression according to the manufacturer’s recommendations. 10 µl of the 
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each sample were measured and luminescence was recorded for 10 seconds using 
a Lumat LB 9507 luminometer (Berthold Technologies, Bad Wildbad, Germany).  
2.5 Transmission electron microscopy 
For morphological analysis, the infected HEp-2 monolayers were fixed with 2% 
glutaraldehyde and 5% formaldehyde in cacodylate buffer (0.1 M cacodylate, 0.9 M 
sucrose, 0.01 M MgCl 2 , 0.01 M CaCl2 , pH 6.9) overnight on ice, washed three times 
with cacodylate buffer, treated with 1% aqueous osmium tetroxide for 1 h at room 
temperature and washed with cacodylate buffer. Samples were then dehydrated with 
a graded series of acetone (10, 30, 50%) on ice for 30 min for each step. Then, 
samples were left in 70% acetone with 0.5% uranyl acetate overnight, and further 
dehydrated with 90% and 100 % acetone. Infiltration of the samples was done with 
the low viscosity epoxy resin according to the described procedure by Spurr [159]. 
Finally, samples were placed into gelatine capsules, filled with pure resin and 
polymerized for 8 h at 70°C. Ultrathin sections were cut with a diamond knife and 
sections picked up with copper grids (300 mesh). Counter-staining of the sections 
was performed with lead-citrate for 2 min. After air-drying, samples were examined in 
a Zeiss EM 910 transmission electron microscope at an acceleration voltage of 80 
kV. 
2.6 Infection of tumour bearing BALB/c mice with L. monocyto-
genes and S. flexneri 
To establish a subcutaneous tumour in BALB/c mice, CT26 or TS/A cells were 
harvested by trypsin treatment, washed once with PBS and resuspended in PBS to 
obtain a single cell solution of 106 – 107 cells/ ml. 100 µl were injected 
subcutaneously into each mouse. Infection was carried out at day 10 after tumour 
transplantation, when tumours were 5 – 8 mm in diameter.  
Bacteria were grown overnight and diluted 1:50 in supplemented TSB medium for 
Shigella or minimal medium for Listeria (see 2.1). Bacterial cultures were grown to an 
optic density at 600 nm (OD600) of ~0.8. Bacteria were then washed as described 
above and resuspended in PBS or PBS + DAP for S. flexneri ∆dap. Mice were 
infected with 106 to 108 CFU, as described in the figure legends. Intravenous and 
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intraperitoneal injections were performed in a total volume of 100 µl per mouse, while 
for intratumoural injection 10 µl per mouse were used. Transgene expression in the 
tumour as well as the number of viable bacteria in the different organs and in tumour 
tissues was determined at indicated time points by plating on appropriate plates.  
To analyze GFP expression in tumour cells, solid tumours were excised from the 
mice. The tissue was first disrupted in cell culture medium using tweezers with sharp 
ends. Subsequently, cells were passed through a cell strainer (100 µm; BD 
Biosciences, Erembodegem, Belgium) to obtain single cell suspensions, which were 
analyzed by flow cytometry using a FACSCalibur (Becton Dickinson, Heidelberg, 
Germany) and CellQuest software (Becton Dickinson). To analyze luciferase activity, 
solid tumours were homogenized in 1 ml PBS supplemented with 0.2 % Igepal 
(Sigma). 125 µl of 5xPLB buffer from the Dual Glo luciferase assay system 
(Promega, Mannheim, Germany) were added to 500 µl of tumour homogenate and 
incubated for 15 min at room temperature. The sample was centrifuged for 1 min at 
full speed in a table top centrifuge and 10 µl of the supernatants were used to 
determine luciferase activity as described above.  
To establish the number of GR-1 positive cells in the tumours of L. monocytogenes 
infected cells, cells were stained in 96 well plates (CellStar, Greiner Labortechnik, 
Frickenhausen, Germany). Single cell suspensions were prepared in FACS buffer 
(2% FCS, 2mM EDTA and 0,1% azid in PBS) at a density 5x105 cell per well. Cells 
were first treated with mouse serum for 15 min on ice, to block Fc receptors, then 
stained for 15 min on ice, using a biotinylated rat-anti-mouse GR-1 antibody 
(Pharmingen, San Diego, USA), and washed with FACS buffer. The biotinylated 
antibody was revealed using streptavidin conjugated with phycoerythrin 
(Pharmingen, San Diego, CA), for 10 min on ice. After washing and staining for dead 
cells with 1 µg/ml of propidium iodide (Sigma-Aldrich, Deisenhofen, Germany) flow 
cytometry was performed using a FACSCalibur (Becton Dickinson, Heidelberg, 
Germany). Data were analyzed with CellQuestPro software (Becton Dickinson, 
Heidelberg, Germany).  
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2.7 Determination of viable bacteria in cell cultures and mouse 
tissues 
The number of viable intracellular bacteria was estimated by plating lysates of in vitro 
infected cells at different time points after infection. Cells were lysed by addition of 
0.1% Triton-X 100 (Serva) in water and incubation for 15 minutes at room 
temperature. Serial dilutions of the lysates were prepared and aliquots were plated 
onto BHI or TSB agar plates, supplemented as described above. The number of 
colony forming units (CFU) was determined and the number of viable bacteria per 
well of a 24-well plate was calculated.  
Alternatively, tissues of mice were homogenized in 1 ml (spleen and tumour) or 2 ml 
(liver) of PBS supplemented with 0.2 % Igepal (Sigma). Serial dilutions were plated 
on appropriate BHI or TSB plates as described above. The number of CFUs was 
determined and the number of viable bacteria per organ or tumour was calculated.  
2.8 Isolation of DNA and Southern blotting 
For the separation of nuclei and cytosol, infected cells were harvested by trypsin 
treatment 48 h after infection and single cell solutions in cold 5% citric acid were 
prepared at a density of 108 cells/ ml or less. To lyse the cells, cold 10% Igepal 
solution (Sigma) was then added to a final concentration of 0.5% while mixing the 
cells thoroughly. The cell suspension was underlayed with a cold solution of 30% 
sucrose/ 0.5% igepal/ 5% citric acid. The gradient was centrifuged for 10 min. at 
2500 rpm in a Beckman GS-6KR centrifuge at 4°C. To obtain DNA present in the 
upper phase of the gradient, 0.3 M sodium acetate, 1 µg/ml glycogen (Böhringer, 
Mannheim, Germany) and 0.7 volumes isopropanol were added and incubated at –
20°C overnight. The precipitate was spun down, washed once with 70% ethanol, air 
dried and resuspended in 10mM Tris-HCl (pH 7.6)/ 1mM EDTA (pH 8.0). The 
sediment containing the nuclei was resuspended in 100mM Tris-HCl (pH 8.5)/ 5mM 
EDTA (pH 8.0)/ 200mM NaCl/ 0.2% SDS. After addition of proteinase K (Sigma) at a 
final concentration of 0.4 mg/ml, the samples were incubated for 14-20 h at 54°C, 
DNA was precipitated by addition of 0.7 vol. of isopropanol and sedimentation at 
13000 rpm in a table top centrifuge. The pellet was washed in 70% ethanol and after 
air drying resuspended in 10mM Tris-HCl (pH 7.6)/ 1mM EDTA (pH 8.0).  
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For southern blot analysis, indicated amounts of DNA from the nuclear fractions and 
the cytosolic fractions were digested with EcoRI. As a standard, different amounts of 
plasmid DNA (as indicated) were mixed with 5 µg of genomic DNA from uninfected 
HEp-2 cells and digested with EcoRI. Subsequently, the samples were separated by 
agarose gel electrophoresis. DNA was then transferred to a nylon membrane (Gene 
Screen plus, Perkin Elmer, Belgium) by capillary force under alkaline conditions. 
After the transfer, the membrane was washed for 1-2 minutes in 2xSSC [139]. DNA 
was fixed to the membrane by UV crosslinking with a Stratalinker 2400 (Stratagene, 
La Jolla, CA), applying 120 mJ.  
The GFP specific probe was obtained by PCR using pERL3-CMVGFP as template 
and oligonucleotides GCGTGTCCGGCGAGGGCGAGGGCG as forward primer and 
GCCGAGAGTGATCCCGGCGGCGG as reverse primer. Radioactive labeling was 
carried out with the Ladderman Labeling Kit (Takara, Japan) according to the 
manufacturers recommendations. The membrane was then prehybridized with 
QuickHyb hybridization solution (Stratagene) for 45 minutes. Afterwards, the 
radioactive probe was added and the membrane was hybridized for 4 h at 65°C. After 
two short washings with 2xSSC/ 0.1% SDS and three times washing with 0.1xSSC/ 
0.1% SDS for 10 minutes at 65°C, the membrane was exposed to a BioMax MS film 
(Kodak, Rochester, NY) for 1-2 h. Alternatively a phosphoimager Storm 860 
(Molecular Dynamics/ Amersham, Freiburg, Germany) was used.  
2.9  Isolation of genomic DNA and PCR analysis of bacterial DNA 
from bacteriofected CHO-K1 cells 
Bacterial chromosomal DNA was isolated as previously described [44]. For isolation 
of DNA from CHO-K1 cells stably transfected by recombinant L. monocytogenes, or 
untreated controls, 107 cells were digested with Proteinase K (200µg/ml) for 48 h at 
55°C in 1 ml Proteinase K buffer (10mM Tris HCl, 5mM EDTA, 1% SDS, 300mM 
NaAc, pH 8,0). The solution was transferred to 7 ml Vacutainer Brand SST tubes 
(Beckton Dickinson, Heidelberg, Germany), where the gel matrix completely 
seperates the organic and aqueous phase. 1 volume of a phenol/chloroform (1:1) 
mixture was added and the sample was mixed and centrifuged for 10 min at 1400 x 
g. To remove remaining traces of phenol, 1 volume of chloroform was added and the 
sample was again mixed and centrifuged. The solution was transferred to 2 ml 
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reaction tubes, DNA was precipitated with 1 volume of absolute ethanol, followed by 
centrifugation for 15 min at >20000 x g. After washing once with 70% ethanol, DNA 
was resuspended in H2O.  
For PCR experiments, the yield of DNA per cell was calculated and a DNA amount 
equivalent to 3000 cells was used as template. The following oligonucleotides 
(Invitrogen, Karlsruhe, Germany) flanking NotI restriction sites in the L. 
monocytogenes genome, were used as primers:  
L.m.RS1-V: 5´-GGTAATCAAACGCCAGTAGGGACT-3´; 
L.m.RS1-R: 5´-ATATGGCGTAGAAGGTTTC GCACC-3´;  
L.m.RS2-V: 5´-AATCCGGTTCACCTGCACCAGTAA-3´;  
L.m.RS2-R: 5´-AA TCAAGCGGCCGCTGATATTGCA-3´;  
L.m.RS3-V: 5´-GGATTTTAAAGCAGTTGCAGC ACG-3´;  
L.m.RS3-R: 5´-TGTCAAAGTCGCTAGAGTAGCGAA-3´;  
L.m.RS4-V: 5´-ATGA ACACGATGGTATCGCCGTTC-3´;  
L.m.RS4-R: 5´-AGGATGGATGCTGCTCGAACG TTT-3´;  
L.m.RS5-V: 5´-GGTCACATTCTCTTCGGCTGCAAT-3´;  
L.m.RS5-R: 5´-CTGGTTTTGAATGGCGTGAACCTG-3´;  
L.m.RS6-V: 5´-CGTTTTATGAACGATTTGGA TGGC-3´;  
L.m.RS6-R: 5´-CTCAATGCAATAGTACTCGACTCC-3´;  
L.m.RS7-V: 5´-ATGCCTGATGCTAGGGTTGGTACA-3´;  
L.m.RS7-R: 5´-TCCTATAAAACAAACGGCTCGCTG-3´.  
As a control, GAP-DH specific primers with the following sequences were used:  
GAPDH FOR: 5’-ATCTTCTTGTGCAGTGCCAGC-3’ 
GAPDH REV: 5’-ACTCCACGACATACTCAGCACC-3’ 
A standard PCR reaction was performed with 40 cycles of amplification using 60°C 
(L. monocytogenes specific primers) or 58°C (GAP-DH specific primers) as annealing 
temperature in a Hybaid Touchdown thermocycler. To determine the sensitivity of the 
PCR assay, the reaction was carried out with serial dilutions of purified genomic DNA 
of L. monocytogenes and DNA from 3000 CHO-K1 cells as a background. Under 
these conditions, specific bands could be detected with all primer pairs used, when 
an equivalent of 10 copies of the L. monocytogenes genome was present in the 
reaction (data not shown). 
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3 Results 
3.1 Optimization and characterization of L. monocytogenes-
mediated gene transfer in vitro 
It is clear that Listeria-mediated gene transfer of therapeutic genes is in principle 
feasible [88]. In previous studies, first reporter genes and subsequently a cDNA 
encoding the cystic fibrosis transmembrane conductance regulator (CFTR) was 
functionally transferred to CHO-K1 and HEp-2 cells in vitro using L. monocytogenes 
[88]. As an extension, a simple reporter system for a facilitated detection of in vivo 
CFTR expression for future studies was established by fusing GFP to the N-terminus 
of CFTR (GFP-CFTR) [188]. The correct intracellular location and functionality of 
both CFTR and GFP-CFTR were shown by immunoblotting, fluorescence microscopy 
and whole cell patch clamp analysis. The number of CFTR channels per cell 
revealed by the latter technique was in a physiological range. However, the number 
of bacteriofected cells was too low to be of clinical benefit. To rationally improve the 
efficiency, it is necessary to understand the mechanism of bacteria-mediated DNA 
transfer in order to find the limiting step. Therefore, as a major part of this work the 
fate of the plasmid DNA after bacterial death was studied.  
3.1.1 Invasion of host cells is not the major limitation 
An obvious step limiting gene transfer efficiency could be the invasiveness of the 
bacteria. Thus, an increase in the number of bacteria taken up by the host cell and 
capable of transferring their plasmid load should enhance bacteriofection. 
Invasiveness of the strain L. monocytogenes hly W491A, which is secreting an 
attenuated listeriolysin [88], could be augmented by culturing the bacteria in minimal 
medium before infection. This leads to the up-regulation of virulence factors that are 
involved in the invasion process of the host cell [72]. Three different cell lines were 
bacteriofected and in parallel the number of intracellular bacteria was determined by 
plating at the start point of antibiotic treatment. Furthermore, the number of GFP 
expressing cells was established by flow cytometry at 48 hrs after initiation of 
bacteriofection.  
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As shown in Fig. 3.1, the number of intracellular bacteria was 5- to 6-fold higher at 
the beginning of antibiotic treatment when bacteria were grown in minimal medium 
compared to rich BHI medium (Fig. 3.1 A). However, the number of transfected cells 
had increased only 2- to 3-fold (Fig. 3.1 B). These results clearly show that invasion 
of the host cell is an important event during the process of bacteria-mediated gene 
transfer. However, it is not the only limiting factor, otherwise the increase in numbers 
of transfected cells should be directly correlated to the increase in numbers of 
intracellular bacteria.  
3.1.2 A minor fraction of the intracellular carrier bacteria transfer plasmids to 
the nucleus of the host cell 
These results stipulated to investigate further whether all bacteria that have entered 
the host cell are able to transfer their plasmid load to the nucleus. To this end, two 
different recombinant strains of L. monocytogenes were used harbouring the 
expression plasmids pERL3-CMVGFP, encoding the green fluorescent protein, and 
pERL3-CMVDsRed2 that encoded a red fluorescent protein. The hypothesis was that 
when all intracellularly lysed bacteria are able to transfer expression plasmids, a co-
infection of HEp-2 cells with both carrier bacteria at high MOIs (740 for pERL3-
CMVGFP and 640 for pERL3-CMV-DsRed2) should result in expression of both 
fluorescent proteins in all cells that could be transfected. This was clearly not the 
case, as shown by fluorescence microscopy 48 hrs after initiation of DNA transfer 
(Fig. 3.2 A). Similarly, when bacteriofected cells were analyzed by flow cytometry, 
only 6.3% of the cells were expressing both proteins (Fig. 3.2 B and C). Despite the 
extremely high MOIs used for both carrier bacteria, 18.1% of the bacteriofectants 
expressed GFP alone and 7.1% were single positive for DsRed2 (Fig. 3.2 B and C). 
Thus, only extremely few of the many carrier bacteria that infect a host cell are able 
to transfer their plasmid load to the nucleus of the host cell. 
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Fig. 3.1: Invasiveness of L. monocytogenes after culture in minimal medium and GFP expression after 
bacteriofection in HEp-2, TS/A and CT26 cells. Cells were infected with L. monocytogenes W491A 
carrying the expression plasmid pERL3-CMV-GFP at a MOI of 200 for HEp-2 and CT26 and 500 for 
TS/A, respectively. (A) The number of viable, intracellular bacteria was determined by plating cell 
lysates on BHI plates with 5 µg/ml erythromycin at 4 hrs p.i. (B) GFP expression was analyzed by flow 
cytometry 24 hrs after bacteriofection. Numbers represent the percentage of viable, GFP expressing 
cells. Data are representative for 1 out of 2 experiments. n.d.: not detectable 
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Fig. 3.2: Co-transfer of expression plasmids pERL3-CMVGFP and pERL3-CMVDsRed to HEp-2 cells 
by L. monocytogenes. Transgene expression was analyzed 48 hrs after bacteriofection. (A) 
Fluorescence micrographs of HEp-2 cells bacteriofected with MOIs of 12 for L. monocytogenes EGD 
carrying pERL3-CMVGFP and 19 for L. monocytogenes EGD carrying pERL3-CMVDsRed. (B) Flow 
cytometric analysis of co-transfected cells. HEp-2 cells were transfected by L. monocytogenes W491A 
carrying the plasmid pERL3-CMVGFP at a MOI of 740 (EGFP only), the plasmid pERL3-CMVDsRed2 
at a MOI of 640 (DsRed2 only) or a mixture of both strains (G1 + R1). Uninfected cells were used as a 
negative control. For gating, cells from the single transfections were mixed (Cells mixed). The 
quantitation of this experiment is shown in (C). This experiment was repeated twice with similar 
results. 
3.1.3 Plasmids liberated from carrier Listeria are not accessible in the cytosol 
of host cells 
A possible explanation for this low transfection rate could be that the plasmids remain 
in the cytosol and are inefficiently transported to the nucleus. Therefore it was argued 
that strong expression should be possible when the complete expression process 
takes place exclusively in the cytosol. To address this point, the carrier bacteria were 
equipped with the plasmid pERL3-T7-IRES-GFP that consists of an EGFP encoding 
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cDNA under the control of the T7 promoter and an IRES from poliovirus type I. As 
host cell the BHK-21 derivative BSRT7/5 was used that constitutively expresses the 
T7 RNA polymerase. Under these circumstances, RNA should be transcribed from 
the plasmid by the T7 polymerase directly in the host cell cytosol and the IRES 
should render the translation of transgene Cap independent. A quick onset of 
transgene expression was expected and, if expression plasmids remained freely in 
the cytosol, a strongly elevated number of cells expressing the transgene.  
To verify this idea, BSRT7/5 cells and BHK-21 cells were first transfected with 
pERL3-T7-IRES-GFP or pERL3-CMVGFP by the calcium phosphate precipitation 
method [139]. Flow cytometry revealed the earliest GFP positive BSRT7/5 cells 
transfected with pERL3-T7-IRES-GFP already after four hours. At this time point, no 
GFP expression was observed in BSRT7/5 cells transfected with pERL3-CMVGFP or 
BHK-21 cells transfected with pERL3-T7-IRES-GFP. Six hours after exposing the 
cells to the DNA precipitate a few GFP expressing cells were found in cells 
transfected with pERL3-CMVGFP (Fig. 3.3 A and C). At 24 hrs, BHK-21 cells 
transfected with pERL3-CMVGFP and BSRT7/5 cells transfected with pERL3-T7-
IRES-GFP showed comparable numbers of GFP expressing cells. Expression from 
the T7 driven plasmids decreased already 48 hrs after transfection while the number 
of GFP positive BSRT7/5 cells transfected with pERL3-CMVGFP was low at 24 hrs 
but increased at 48 hrs after transfection. 
When similar transfections were performed as bacteriofections using L. 
monocytogenes W491A carrying the corresponding plasmids, early onset of 
transgene expression in BSRT7/5 cells bacteriofected with pERL3-T7-IRES-GFP 
was no longer observed (Fig. 3.3 B and C). GFP positive cells were only found after 
24 and 48 hrs in BHK-21 cells bacteriofected with pERL3-CMVGFP. Remarkably, 
transfection of BSRT7/5 cells with Listeria using pERL3-CMVGFP as expression 
plasmid led to a low transgene expression after 48 hrs. The cause of this effect could 
not be explained at the moment. 
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Fig. 3.3: Bacteriofection of BHK-21 and BSRT7/5 cells with a plasmid potentially expressed in the 
cytosol of host cells. BHK-21 and BSRT7/5 cells were transfected with the plasmids pERL3-CMVGFP 
and pERL3-T7-IRES-GFP, respectively, by either calcium phosphate precipitation (A) or by L. 
monocytogenes W491A mediated gene transfer (B). The number of living, GFP expressing cells was 
measured by flow cytometry at 2, 4, 6, 24 and 48 hrs after initiation of DNA transfer. (C) Flow 
cytometric analysis at 6 hrs post transfection. Dots in the upper right quadrant represent viable, GFP 
positive cells. BHK: BHK-21 cells, BSR: BSRT7/5 cells, control CaPO4: mock transfected cells, control 
L. monocytogenes: uninfected cells, CMV: transfection with plasmid pERL3-CMVGFP, T7: transfection 
with plasmid pERL3-T7-IRES-GFP. Significant expression could be detected only when the plasmid 
was transfected by calcium phosphate precipitation. 
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3.1.4 Bacteria are efficiently lysed and their content is released after 
treatment with antibiotics 
The above results suggest that most plasmids introduced into the host cells by L. 
monocytogenes do not become accessible to the host cells expression mechanisms. 
They might be either associated with proteins, possibly of bacterial origin or they 
might be rapidly degraded. To distinguish between these possibilities the fate of the 
bacteria after treatment with antibiotics was first analyzed since the plasmids might 
remain associated with lysed bacteria. To this end, the number of viable bacteria 
during the course of the experiment was established by plating, as shown in Figure 
3.4. Already 24 hrs after the addition of the antibiotics the number of colony-forming 
bacteria dramatically decreased and by 48 or 72 hrs hardly any platable bacteria 
were found.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4: Intracellular bacteria are efficiently killed by addition of antibiotics. HEp-2 cells were infected 
with L. monocytogenes W491A carrying the expression plasmid pERL3-CMVGFP at a MOI of 400. 
The number of viable intracellular bacteria was determined by plating cell lysates at different time 
points after addition of penicillin/ streptomycin. CFU, colony forming units. 
 
 
This was confirmed using fluorescent live/dead staining for bacteria. Only a few live 
bacteria were detected at time points later than 24 hrs following initiation of antibiotic 
treatment (data not shown). Interestingly, also the number of detectable dead 
bacteria decreased dramatically under these circumstances (data not shown). Since 
the determination of dead bacteria is based on the staining of bacterial DNA with 
47 
propidium iodide that can be discerned as red fluorescent entities within the host 
cells cytosol, these data suggest that the content of the bacteria is no longer 
concentrated within the bacteria.  
Therefore transmission electron microscopy was employed to directly examine the 
fate of the bacteria. Figure 3.5 A shows that, at the time of adding antibiotics, 
bacteria had an intact structure and were found either in typical phagocytic vacuoles 
or already in the cytosol. At 24 hrs, bacteria that are only partially filled with electron 
dense material could be found and some structures which obviously represent lysed 
bacteria or bacteria that are at the verge of releasing their content into the cytosol 
were observed (Fig 3.5 A arrows). Similar structures were detected at later time 
points, although they become rather rare at 48 and 72 hrs.  
Interestingly, at 24 hrs and later, several bacteria are still found in vesicles. At this 
time all bacteria would have been expected to have escaped into the cytosol. 
Apparently, such vesicles fuse with lysosomes (Fig. 3.5 B arrows).  
The electronmicrographs indicated that the bacterial content is released quickly into 
the cytosol of the host cell after adding the antibiotics. This suggests that bacterial 
proteins and other macromolecules should be found in the cytosol of the host cell, 
shortly after bacterial lysis. Therefore Listeria that heterologously expressed GFP 
under the control of a bacterial promoter (pERL3-cspl::gfp; [88]) were employed.  
As shown in Fig. 3.6 B, already at the initiation of the antibiotics treatment 80% of 
infected cells contain significant amounts of GFP. However, GFP was exclusively 
associated with bacteria as observed by fluorescence microscopy (3.6 A). Roughly 
the same number of cells still contained GFP 48 hrs later (Fig. 3.6 B), but at this time 
point hardly any bacteria could be observed within the host cells. In addition, GFP 
was now evenly distributed over the entire host cell (data not shown). The 
fluorescence intensity observed after 48 hrs was similar to that detected at the time 
when antibiotic treatment was started, but was significant lower than seen after 
Listeria-mediated DNA transfer. Apparently, GFP expressed by the bacteria is 
released upon lysis of the bacteria into the cytosol of the host cell. 
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Fig. 3.5: Bacteria are efficiently lysed and their cell walls disrupted after antibiotic treatment. (A) 
Transmission electron micrographs of L. monocytogenes W491A infected HEp-2 cells at different time 
points after addition of antibiotics. Arrows indicate disrupted bacterial cell walls. Interestingly, despite 
of the long time after invasion many bacteria are found in vacuoles. In (B) the aggregation of 
lysosomes at sites of bacterial degradation is shown. The arrow indicates the fusion of a lysosome 
and a bacteria containing vesicle. Black bars correspond to 1 µm. L: Lysosome; N: Nucleus. 
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Fig. 3.6: Bacterial content is efficiently released into the host cell cytosol after bacterial lysis. (A) 
Fluorescent micrograph of a HEp-2 cell infected with L. monocytogenes W491A constitutively 
expressing GFP. Cells were analyzed just before start of antibiotic treatment. (B) Flow cytometric 
analysis of HEp-2 cells after infection with L. monocytogenes W491A constitutively expressing GFP 
(pERL3-cspl::gfp). 0h: cells were analyzed just before addition of antibiotics. 48h: cells were analyzed 
48 hrs after the addition of antibiotics. Fluorescent micrographs of cells at that time point are not 
shown since the signal was too low to be recorded. Flow cytometry can reveal the presence of GFP 
since it displays an integration of the signal over the entire volume of the cell. Uninfected HEp-2 cells 
were used as negative control (not infected). 
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3.1.5 Transferred plasmids are associated with fast sedimenting entities  
Following efficient release of the bacterial content the plasmid DNA should remain 
detectable in the cytosol of the host cell unless it is rapidly degraded. Therefore, 
HEp-2 cells were infected with L. monocytogenes W491A carrying the plasmids 
pERL3-CMVGFP and pERL3-CMVGFPCFTR-neo, respectively. The infected cells 
were lysed 48 hrs after infection and the lysate was centrifuged over a 30% sucrose 
cushion to separate the cell nuclei from soluble cytosolic compounds. DNA was 
isolated from both fractions and analyzed by Southern blotting. To estimate the 
number of plasmids in the nuclear and cytosolic fractions, three different amounts of 
pERL3-CMVGFP plasmid DNA mixed with HEp-2 genomic DNA were loaded onto 
the gel for comparison. Results are shown in Fig. 3.7. Signals specific for EGFP were 
found exclusively in the fraction sedimenting through the sucrose cushion when cells 
bacteriofected with pERL3-CMVGFP and pERL3-CMVGFPCFTR-neo were tested, 
respectively. No signals were detectable in the cytosolic fractions of these cells. 
Soluble plasmid DNA added to the cell lysate just before centrifugation was to a large 
extent found in the cytosolic fraction (data not shown). By comparing the intensity of 
signals from nuclear fractions with the plasmid standard, it was estimated that the 
number of plasmids recovered was in the range of the number of plasmids carried by 
the intracellular bacteria that were added at the time of infection. Keeping in mind the 
low transfection efficiency, it is highly unlikely that all plasmids were transferred into 
the nucleus. Therefore, the interpretation of the above result is taken as evidence 
that the plasmid DNA is associated with macromolecules that are of sufficient mass 
to sediment through the sucrose cushion during the separation of cell nuclei from 
cytosolic compounds. Furthermore, it clearly shows that the plasmid DNA is not 
degraded rapidly, but remains within the host cell for a considerable amount of time. 
3.1.6 Integration of bacterial DNA into the host cell genome after L. 
monocytogenes mediated gene transfer 
The rapid release of the complete bacterial content upon lysis of L. monocytogenes 
within eukaryotic cells, also results in the release of large quantities of bacterial 
chromosomal DNA. This could in turn result in transfer and subsequent integration 
into the host cell genome. To test this possibility, genomic DNA was isolated from 
different CHO-K1 derived cell lines and clones that had been bacteriofected with L. 
51 
monocytogenes. A PCR was performed using 7 primer pairs to scan and detect 
fragments of the listerial chromosome. The primer pairs that were selected did not 
show any amplification product with DNA from the parental CHO-K1 cells (data not 
shown). A DNA-amount equivalent to 3000 CHO-K1 genomes was tested. The 
sensitivity of this assay allowed reproducibly the detection of DNA-amounts 
equivalent to 10 L. monocytogenes genomes. 
 
 
 
Fig. 3.7: Southern blot analysis of nuclear and cytosolic fractions of bacteriofected HEp-2 cells. Cells 
were lysed 48 hrs post infection with Igepal and fractionated by centrifugation over a 30% sucrose 
cushion. DNA was isolated by isopropanol precipitation Standard: pERL3-CMVGFP plasmid DNA 
mixed with HEp-2 genomic DNA as carrier DNA. Lm GFP: Nuclear fractions from HEp-2 cells 
transfected by L. monocytogenes W491A carrying the plasmid pERL3-CMVGFP. Lm GFP-CFTR: 
Nuclear fractions from HEp-2 cells transfected by L. monocytogenes W491A carrying the plasmid 
pERL3-CMVGFPCFTR-neo. GFP SN/ GFPCFTR SN: corresponding cytosolic fractions after 
concentration by isopropanol precipitation. 
 
First, the cell line ST37, which was stably transfected with a GFP-CFTR encoding 
plasmid by L. monocytogenes, was tested. A specific signal was obtained for all 7 
primer pairs (Fig. 3.8). When this cell line was further sorted for GFP expressing cells 
(ST37-S1), only 3 of the 7 bands remained detectable. Repeated sorting of medium 
and high fluorescent cells from the ST37-S1 population resulted in the two 
subpopuations ST37-S2H and ST37-S2M, but neither of them gave rise to specific 
amplification products. The same was true for the clone ST37-2H.43 derived from 
ST37-S2H and for 2 clones, ST37-2M.12 and ST37-2M.19, derived from the ST37-
S2M line.  
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Fig. 3.8: Presence of DNA fragments derived from the bacterial chromosome in the genome of CHO-
K1 cells after L. monocytogenes-mediated gene transfer. Primer pairs (1-7) were specific for L. 
monocytogenes genomic DNA or GAP-DH (C). All cell lines and clones were derived from CHO-K1 
and stably transfected by L. monocytogenes-mediated gene transfer. ST37, bulk culture expressing 
GFP-CFTR; ST37-S1, GFP positive subpopulation of ST37; ST 37-S2M, medium fluorescent 
subpopulation of ST37-S1; ST37-S2H, high fluorescent subpopulation of ST37-S1; ST37-2M.12 and 
ST37-2M.19, clones derived from ST37-S2M; ST37-2H.43, clone derived from ST37-S2H; GFP-S1+ 
and GFP-S1-, GFP positive and negative subpopulations of a bacteriofection employing the GFP-
encoding plasmid pERL3-CMVGFP-neo; GFP-S2+ and GFP-S2-, positive and negative subpopulations 
of a bacteriofection employing the GFP-encoding plasmid pERL3-EPI1, a supposedly episomally 
replicating eukaryotic expression plasmid [128]. Results shown are representative for at least 3 
independent experiments. 
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To confirm these results, cells bacteriofected with plasmids other than the GFP-
CFTR encoding plasmid were also examined. Again CHO-K1 cells stably transfected 
by L. monocytogenes with the GFP-expressing plasmids pERL3-CMVGFP-neo or 
pERL3-EPI1 showed specific bands for all 7 primer pairs (data not shown). In 
contrast, the neomycin resistant but GFP negative subpopulation of the pERL3-
CMVGFP-neo bacteriofection (Fig. 3.8, GFP-S1-) displayed a single amplification 
product, whereas the GFP positive fraction exhibited two such products (Fig. 3.8 
GFP-S1+). Cells bacteriofected with the plasmid pERL3-EPI1 were also sorted for 
GFP positive (GFP-S2+) and negative (GFP-S2-) populations and showed either no 
or two specific amplification products, respectively. PCR from 5 clones from a 
transfection using the β-galactosidase encoding plasmid pERL3-CMVβ-neo did not 
result in any primer specific bands (data not shown). Thus, the more homogenous a 
bacteriofected cell population becomes, the less DNA from the bacterial chromosome 
can be detected. These results indicate that integration of L. monocytogenes 
chromosomal DNA into the host cell genome occurs, but appears to be a rare event 
and probably involves only small fragments of bacterial DNA. 
3.2 L. monocytogenes-mediated gene transfer in vivo 
The original protocol of L. monocytogenes-mediated gene transfer was aimed at 
gene therapy of Cystic Fibrosis. In that case, the target cell for therapy should be 
accessible to the bacterium and the ability of L. monocytogenes to spread from cell to 
cell should target also stem cells of the airway epithelium. However, in this work, the 
potential of L. monocytogenes-mediated gene transfer should be explored in other 
applications. Recently, several species of intracellular bacteria have been shown to 
specifically accumulate in tumour tissues when systemically administered to tumour 
bearing mice [7; 71; 137; 186]. Since the original experiments were performed in 
immunocompromised animals, it was decided to show a proof of principle by 
characterizing the infection via the intratumoural route, using BALB/c mice 
transplanted subcutaneously with the TS/A tumour as a model system. Also, the 
impact of antibiotic treatment of mice on the course of infection and gene transfer 
should be addressed. 
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3.2.1 Characterization of L. monocytogenes infection and gene transfer in 
tumour bearing BALB/c mice 
BALB/c mice were subcutaneously injected with tumour cells derived from the 
methylcholantren induced breast cancer TS/A. When tumours had reached 5 – 8 mm 
in diameter, L. monocytogenes EGD carrying the eukaryotic expression plasmid 
pERL3-CMVGFP were injected directly into the tumour tissue and the number of 
viable bacteria was established by plating dilutions of tumour and organ 
homogenates at different time points after the infection. Mice were divided into two 
groups of which one received treatment with ampicillin with the intention to control 
the infection and at the same time to initiate lysis of bacteria and gene transfer. The 
other group did not receive antibiotic treatment. As shown in Fig. 3.9, high numbers 
of bacteria could be found in tumours at 12 hrs post infection (p.i.). However, the 
bacteria were not completely contained within the tumour tissue, as could be 
expected from recent data [186]. Listeria were detected in liver and spleen as early 
as 12 hrs p.i., although at low numbers. In mice that received no antibiotic treatment 
(Fig. 3.9 A), Listeria were able to replicate in liver and spleen and by 60 hrs p.i., the 
total numbers of CFUs in these organs were comparable to those found in the 
tumours at the same time point. In contrast, the number of viable bacteria in the 
tumour tissue was constant or increased only slightly over time.  
When mice were treated with ampicillin (Fig. 3.9 B), the bacterial load in liver and 
spleen still increased as seen at 36 hrs p.i. could be observed. The number of 
bacteria then was decreased at 60 hrs p.i. In the tumours, bacterial numbers 
decreased with time leading to a 10 to 100 fold reduction at 60 hrs p.i. Thus, despite 
antibiotic treatment starting at 12 hrs p.i. significant numbers of viable bacteria could 
still be found at later time points, indicating that efficient antibiotics treatment in vivo 
might require higher ampicillin concentrations. 
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Fig. 3.9: Distribution of L. monocytogenes after intratumoural infection of BALB/c mice. Mice were 
infected with 5x105 L. monocytogenes W491A carrying the expression plasmid pERL3-CMVGFP. 
Bacteria were grown in minimal medium prior to infection. Antibiotic treatment was initiated at 12 hrs 
p.i. Mice received 2 mg ampicillin i.p. every 12 hrs until the end of the experiment. Two individual mice 
per group were used. Symbols represent the average value with error bars indicating the range of the 
lowest and the highest values, respectively. 
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To see if gene transfer and transgene expression from the eukaryotic expression 
plasmid carried by the Listeria took place in the tumour, cells were isolated from 
these solid tumours and analyzed for GFP expression by flow cytometry (Fig. 3.10). 
Due to the isolation procedure, a large number of dead cells were observed during 
analysis of all tumours. However, GFP expression could not be detected in individual 
tumours. No difference to the non-infected controls could be observed. However, a 
strong influx of GR-1 positive cells, most likely neutrophilic granulocytes, into the 
tumour tissue was observed (Fig. 3.11). This was in accordance with the role of 
granulocytes in L. monocytogenes infection (see also Introduction). 
 
 
 
 
 
Fig. 3.10: Analysis of transgene expression after in vivo bacteriofection. Tumour cells were isolated 
from BALB/c mice that were infected intratumourally with 5x105 L. monocytogenes W491A carrying 
the plasmid pERL3-CMVGFP. Transgene expression was analyzed 48 hrs after start of antibiotic 
treatment. No GFP expression could be detected in two individual tumours (tumour1 and tumour2, 
respectively; black lines). CTRL: tumour cells isolated from a non-infected mouse (grey lines). 
Numbers in the upper right quadrant represent the percentage of viable, GFP positive cells. This 
experiment was repeated twice with similar results. 
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Fig. 3.11: A strong influx of GR-1 positive cells is found in tumours of mice infected with 
L. monocytogenes. Cells were isolated from tumours of BALB/c mice 48 hrs after intratumoural 
infection with L. monocytogenes W491A carrying the plasmid pERL3-CMVGFP. GR-1 expression was 
analyzed by using a monoclonal anti-GR-1 antibody. CTRL: cells isolated from non-infected mice. 
Tumour1 and Tumour2: cells isolated from tumours of two individual mice. Grey lines: cells incubated 
with only the secondary antibody. Black lines: cells stained with anti-GR-1 antibody. Numbers 
represent the percentage of viable, GR-1 positive cells. 
3.3 S. flexneri-mediated gene transfer 
Since in vivo gene transfer into tumour cells could not detectably be mediated by L. 
monocytogenes under our conditions, it was decided to turn the attention to another 
intracellular bacterium, the Gram-negative bacterium Shigella flexneri. Two different 
attenuated strains (S. flexneri ∆aroD and S. flexneri ∆dap) were used to characterize 
infection and gene transfer first in vitro in different cell lines, and subsequently in vivo 
in a mouse tumour model. Growth of both strains is dependent on metabolites that 
are not available inside the mammalian host cell. Therefore, a treatment with 
antibiotics to kill intracellular bacteria and initiate gene transfer should not be 
necessary.  
58 
3.3.1 Characterization of S. flexneri-mediated gene transfer in different cell 
lines in vitro 
S. flexneri ∆aroD and S. flexneri ∆dap, both carrying the eukaryotic expression 
plasmid pCMVGFP were used to bacteriofect three different cell lines (BHK-21, CT26 
and HEp-2) in vitro. As shown in Fig. 3.12, up to 2.6% of HEp-2 cells bacteriofected 
with the ∆aroD strain at a MOI of 78 expressed GFP 24 hrs after bacteriofection. For 
BHK-21 and CT26 cells, approximately 1.5% of the cells were transfected. 
Transfection rates were not significantly enhanced when higher MOIs of up to 500 
were used (data not shown). Furthermore, transfection rates were comparable with 
and without antibiotic treatment, demonstrating that death of intracellular bacteria and 
gene transfer does not require antibiotics.  
Similar results were obtained when using the ∆dap strain of S. flexneri at a MOI of 
300, although the overall transfection rates were slightly lower compared to the 
∆aroD strain. Small differences were also seen between cells treated with antibiotics 
and non treated cells, with lower transfection rates in non treated HEp-2 and BHK-21 
cells, while in CT26 cells, higher transfection rates were observed in non treated 
cells. However, this could be due to variations within the experiments.  
GFP has proved very useful as a reporter gene to characterize bacteriofection in 
vitro, especially because it allows the detection of single bacteriofected cells and the 
level of expression per cell by flow cytometry. Nevertheless, it is not a good reporter 
gene for in vivo studies in our case. Cells that are infected with bacteria (and 
therefore are dying or about to die) show high levels of autofluorescence that cannot 
be easily distinguished from low levels of GFP expression. Therefore fire fly 
luciferase was used as an alternative reporter gene for Shigella-mediated gene 
transfer. This enzyme requires less time to become detectable compared to GFP. In 
addition, extremely low background activity is observed in mammalian cells and 
tissues. Therefore, also low expression levels can be detected by measuring 
luminescence.  
 
59 
 
 
Fig. 3.12: In vitro bacteriofection of different cell lines with attenuated S. flexneri strains. GFP 
expression was analyzed 48 hrs after bacteriofection (A) HEp-2, BHK-21 and CT26 cells were 
bacteriofected with S. flexneri ∆aroD carrying the expression plasmid pCMVGFP at a MOI of 78. (B) 
HEp-2, BHK-21 and CT26 cells were bacteriofected with S. flexneri ∆dap carrying the expression 
plasmid pCMVGFP at a MOI of 300. + Pen/Strep: penicillin/ streptomycin was added to the cells 4 hrs 
p.i. – Pen/Strep: no penicillin/ streptomycin was added to kill intracellular bacteria. The percentage of 
viable, GFP positive cells is shown as determined by flow cytometry.  
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To test the Shigella ∆aroD and ∆dap strains carrying the eukaryotic expression 
plasmid pCMV-luc-m2A (Bauer, H.; unpublished) for their in vitro transfection 
efficiency, again the three cell lines HEp-2, BHK-21 and CT26 were used. After 24 
hrs and 48 hrs, the number of intracellular bacteria was determined in parallel to 
luciferase activity in the cell lysates (Fig. 3.13). After infection with S. flexneri ∆aroD, 
luciferase activity was detected in all cell lines tested, although considerable 
differences were observed between the three cell lines (Fig. 3.13 A). The highest 
activity after 24 hrs was detected in BHK-21 cells compared to HEp-2 and CT26 
cells, which showed comparable activities. Luciferase expression had increased in 
BHK-21 and HEp-2 cells, and reached comparably high levels in these two cell lines 
by 48 hrs, while expression in CT26 cells remained constantly low. At this time, only 
very few viable intracellular bacteria could still be found (Fig. 3.13 C). This again 
indicates that antibiotic treatment is not required when using the attenuated S. 
flexneri ∆aroD strain.  
The luciferase activity in all cell lines was lower when the S. flexneri ∆dap strain was 
used for bacteriofection (3.13 B). At 24 hrs, activity was again highest in BHK-21 
cells, while in CT26 cells, expression barely raised over the background 
luminescence. At 48 hrs, the expression level increased in all cell lines, again most 
strongly in BHK-21 cells. For unknown reasons, the number of remaining viable, 
intracellular bacteria did not correlate with the level of expression (Fig. 3.13 D). In 
most cases, numbers of viable ∆dap bacteria were higher compared to ∆aroD 
bacteria. 
3.4 S. flexneri-mediated gene transfer in vivo 
To investigate whether the two Shigella strains tested in vitro are suitable for gene 
transfer into tumour cells in vivo, a similar model system was used as described 
above for Listeria-mediated gene transfer. Two modifications were introduced: first, 
the tumour cell line CT26, which is derived from a mouse colon carcinoma, was used 
instead of TS/A, and second, GFP was exchanged for luciferase as a reporter gene 
for the reasons mentioned above. In addition, three different routes of infection 
(intraperitoneal, intravenously and intratumoural) were employed to test the ability of 
S. flexneri to accumulate in tumour tissues when administered to BALB/c mice. 
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Fig. 3.13: In vitro bacteriofection of different cell lines with attenuated S. flexneri strains carrying the 
expression plasmid pCMV-luc-m2A. Luciferase expression and the number of viable, intracellular 
bacteria were determined 24 and 48 hrs after bacteriofection. In (A) and (B), BHK-21, HEp-2, and 
CT26 cells were bacteriofected with S. flexneri ∆aroD and ∆dap, respectively and enzymatic activity of 
luciferase was determined. (C) and (D) show the number of intracellular ∆aroD and ∆dap bacteria, 
respectively, as determined by plating on TSB plates with ampicillin. n.d.: not detectable 
3.4.1 Characterization of S. flexneri infection and gene transfer in tumour 
bearing BALB/c mice 
After infection with the two S. flexneri strains ∆aroD and ∆dap, the number of viable 
bacteria in liver, spleen and tumour tissue was determined by plating serial dilutions 
of tumour and organ homogenates at different time points after infection. When the 
bacteria were given by the intratumoural route, a distribution pattern of bacteria was 
found similar to intratumoural infection by L. monocytogenes (Fig. 3.14 A). Using the 
∆aroD strain, high numbers of Shigella were detected in the tumours of mice 24 hrs 
after infection, and the number of viable bacteria stayed constant during 48 and 72 
hrs. This is in contrast to the observations made by the in vitro experiments, where 
only very few bacteria were found at these late time points p.i.  
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Fig. 3.14: Distribution of attenuated S. flexneri strains in tumour-bearing BALB/c mice after 
intratumoural infection. Mice were infected with 106 S. flexneri ∆aroD (A) or 108 S. flexneri ∆dap (B). 
The number of viable bacteria was determined by plating of homogenates of tumours and organs at 
indicated time points. Values represent the average of three individual mice per group (mean +/- s.d.). 
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Bacteria could also be detected in the liver and spleen of mice for a period of 72 hrs, 
albeit at much lower numbers than in the tumour. In spleen, the bacterial load stayed 
constant during the observation period, while in the liver it decreased.  
After systemic administration via the intraperitoneal or intravenous route, no bacteria 
were detected at any time point in any organ or tissue (data not shown). This is in 
accordance with the fact that S. flexneri is not infectious in mice.  
Alternatively, mice were infected with Shigella ∆dap intratumourally (Fig. 3.14 B) and 
the bacterial load in tumour, liver and spleen was monitored over a period of 7 days. 
Again, high numbers of viable bacteria were found in tumours until day 4. On day 7, a 
decrease of the bacterial burden in the tumour was observed in a single mouse, 
while it remained high in the others. CFUs were significantly lower in liver and spleen, 
and the bacterial load decreased slightly with time. When Shigella ∆dap was given by 
the intraperitoneal or intravenous route, only very few bacteria were detected in 
tumours and the organs tested (data not shown), demonstrating that S. flexneri ∆dap 
as well as ∆aroD do not accumulate specifically in tumour tissues in BALB/c mice 
after systemic administration.  
Since Shigella-mediated gene transfer was observed in vitro, the two recombinant 
attenuated strains were also tested for their ability to mediate gene transfer in vivo. 
CT26 bearing BALB/c mice were infected intratumourally with S. flexneri ∆aroD and 
∆dap carrying the eukaryotic expression plasmid pCMV-luc-m2A. Transgene 
expression was monitored at 24 and 48 hrs after infection (Fig. 3.15 A). At the same 
time, the number of viable bacteria in the tumour tissue was established by plating 
(Fig. 3.15 B).  
Since the CMV immediate early promoter shows some activity also in bacteria [52], it 
was necessary to establish that the detected luciferase activity was not derived from 
bacterial expression but resulted from in vivo gene transfer. To account for this 
possibility, an aliquot of the original inocculum was lysed under the same conditions 
as the tumour tissue and the supernatant was analyzed for luciferase.  
Luciferase activity was detected in tumours of infected mice, although the signal 
strength varied considerably between individual animals (Fig. 3.15 A). However, the 
bacteria also produced some luciferase, despite the eukaryotic CMV promoter used 
to drive luciferase expression (data not shown). Additionally, the signal intensity 
correlated with the number of viable bacteria in tumours. Elevated levels of luciferase 
activity were observed in tumours, but at the moment, it cannot unambiguously be 
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concluded that gene transfer took place and the luciferase detected was synthesized 
by the eukaryotic cells. Since in vivo gene transfer with S. flexneri was demonstrated 
in other systems [147; 154], it can be assumed that gene transfer can take place to a 
certain extend also under the conditions found here. Thus, further work is required to 
establish bacteria-mediated gene transfer in vivo for gene therapy of cancer.  
 
 
 
 
Fig. 3.15: In vivo gene transfer and number of viable bacteria in tumour tissues after intratumoural 
infection of CT26 bearing BALB/c mice with 5x107 S. flexneri attenuated strains. (A) and (C): 
Luciferase activity 24 and 48 hrs p.i. in tumour tissues of mice infected with S. flexneri ∆aroD and 
∆dap, respectively, carrying the plasmid pCMV-luc-m2A. (B) and (D): Numbers of viable bacteria in 
tumour tissues were established by plating of tumour homogenates 24 and 48 hrs p.i. PBS: Mice were 
injected with PBS; aroD, dap: mice were infected with the parental bacterial strain without a plasmid. 
1, 2 and 3 are individual mice. n.d.: not detectable. 
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4 Discussion 
4.1 The mechanism of DNA transfer by L. monocytogenes 
An in vivo application of the Listeria-mediated DNA transfer system, for instance to 
treat monogenic disease or cancer, has to satisfy several prerequisites, the most 
important one being a sufficient transfection rate of the target tissue. At the moment, 
the number of cells transfected even in vitro is still rather low. It is therefore of utmost 
importance to find out the mechanism of DNA transfer in molecular terms, in order to 
understand its limitations and then, subsequently, eliminate such restrictions.  
There are three obvious steps that might limit the process of bacteria-mediated gene 
transfer: I) invasion of the host cell; II) bacterial lysis and plasmid release; III) stability 
and transport of the expression plasmid to the nucleus. 
 
Invasion of the host cell 
From our former data [60; 88] and data presented here it seems that invasion of the 
host cell by the bacteria is not a critical step since most cells are infected and contain 
several bacteria. When L. monocytogenes were grown in minimal medium which 
leads to the upregulation of virulence factors involved in cell invasion, a 5- to 6-fold 
increase in the numbers of intracellular bacteria during infection was observed. 
However, only a 2- to 3-fold increase of transfected cells could be detected. Thus, 
augmented invasion of the host cell can enhance transfection efficiencies, but 
transfer efficiency is not directly correlated with invasiveness of the bacteria. This 
leads to the conclusion that only a fraction of the intracellular bacteria are able to 
eventually transfer their plasmid load to the nucleus of the host cell. 
 
Bacterial lysis and plasmid release 
The idea that only very few bacteria transfer their plasmid was further substantiated 
in an experiment in which cells were cotransfected with two different plasmids by L. 
monocytogenes. Relatively high numbers of cells were found that expressed only 
one transgene, suggesting that normally only a few or even a single plasmid is 
transferred to the nucleus. However, the high transgene expression levels that were 
observed in transfected cells are opposed to the suggestion that the transgene is 
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expressed from only a single copy of the plasmid. Thus, the transfer of bundled 
plasmids derived from a single bacterium under these conditions is more likely. 
Bacteria are efficiently lysed within the cytosol of the host cell upon antibiotic 
treatment. Their cell walls were disrupted quickly and the bacterial content was 
released as revealed by electron microscopy. This was confirmed by showing that 
the GFP protein expressed by the bacteria is quickly distributed within the cytosol of 
the eukaryotic host cell upon bacterial lysis. Virtually all cells that were initially 
infected contained evenly distributed GFP 48h after antibiotic treatment. 
Consequently, the efficiency of bacterial lysis and release of the bacterial content into 
the cytosol of host cells should be high enough to allow effective gene transfer.  
 
Stability and transport of the expression plasmid to the nucleus 
One possibility why transfection rates are low could be that the DNA transferred by 
bacteria is degraded in the host cell’s cytoplasm. It could be shown, however, that 
low transfer rates are not due to rapid degradation of the plasmids since large 
amounts of intact plasmids could be recovered even 48 h after initiation of antibiotics 
treatment. Rather, the plasmids appear to be associated with macromolecules or 
organelles as indicated by their sedimentation properties. Spiking the lysates with 
control plasmids showed that the high sedimentation rate of the bacterially introduced 
plasmids is most likely not an artefact of the lysis procedure. Most of the control 
plasmids could be recovered in the slowly sedimenting fraction containing the 
cytosolic proteins during these experiments.  
This was corroborated by an experiment using a plasmid from which the transgene 
should be expressed in the cytosol of the host cell. After transfer by L. 
monocytogenes, the transgene was not expressed. This again suggests a strong 
association of the plasmid with cellular or bacterial components and would also 
explain the discrepancy found between plasmids introduced by calcium phosphate 
transfection as compared to bacteriofection.  
Thus, the most important limitation for an efficient gene transfer using L. 
monocytogenes as carrier, and its application in vivo, is the association of the 
plasmid DNA with macromolecules or organelles after the lysis of the bacteria.  
The next step should be now to further characterize these complexes. For instance, 
the fractionation should be carried out in a more sophisticated way to determine the 
exact size of the complexes. If organelles are involved, they should be characterized 
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by microscopical and biochemical means. Upon these results, it might be possible to 
modify the plasmids or the associated macromolecules in a way that facilitates 
transfer of DNA to the nucleus. For instance, DNA binding proteins might be 
expressed in the bacteria that contain eukaryotic nuclear localisation signals which 
might solve the present problems. 
4.2 Integration of bacterial genomic DNA into the host cell genome 
Since high bacterial MOIs were used under our bacteriofection conditions, it was 
plausible that fragments of the bacterial chromosome can also reach the nucleus of 
the host cell. It was therefore important to clarify the fate of the bacterial genomic 
DNA released from lysed L. monocytogenes in the host cell cytosol. To avoid listerial 
DNA that might have been only transiently present after infection, we employed 
stable bacteriofectants that had been in culture for a considerable time. Under these 
circumstances, bacterial DNA is diluted out due to cell division unless it is integrated 
into the genome of the host cell. Only then can it be replicated and stably distributed 
to the daughter cells.  
Chromosomal DNA of L. monocytogenes was detected in the genomic DNA of the 
transfected host cell. However, the more homogenous a cell population was, the less 
bacterial DNA was detected. In sorted subpopulations only a few specific signals 
could be observed, while in all of the clones analyzed so far, no bacterial DNA was 
found.  
The sequences that are covered by the primer pairs represent only about 0.15% of 
the L. monocytogenes chromosome. Thus, bacterial DNA could have been present 
but was not detected. Despite of this possibility, one can conclude that integration of 
bacterial chromosomal fragments, although clearly taking place, is a rare event under 
our conditions. Whether the mechanisms leading to plasmid and bacterial DNA 
transfer are identical remains to be investigated. 
Integration of bacterial chromosomal DNA could represent a severe safety risk.  
Integration into the LMO2 proto-oncogene locus by the retroviral vector used for the 
gene therapy of an immunological defect in two children has recently resulted in the 
induction of cancer [56]. This was most likely due to a strong retroviral enhancer 
activity on the LMO2 gene promoter. It is however unlikely that a similar scenario 
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takes place due to the integration of bacterial DNA. Bacterial control elements are 
notoriously weak in the mammalian cells if active at all.  
Integration of DNA fragments could also result in the inactivation of a tumour 
suppressor gene. However, this will take place only on one chromosome leaving the 
second allele intact. Nevertheless, despite the low frequency that was suggested by 
the experiments described, a finite risk remains and the most effective solution of this 
problem would be to significantly raise the efficiency of the gene transfer. This would 
allow a dramatic reduction of the MOI and consequently lead to a strongly reduced 
risk of cotransfer of bacterial chromosomal DNA. 
4.3 Bacteria-mediated gene transfer in tumour therapy 
4.3.1 L. monocytogenes 
So far data on successful transfer of expression plasmids using L. monocytogenes 
as carrier are rather limited. In fact, only low transfer rates were reported into 
peritoneal macrophages in the cotton rat. Therefore, it was argued in the present 
work that if Listeria of the current design can be used as vectors, direct injection into 
tumour tissue should be the most promising approach. The target cells should be 
directly infected and cell to cell spread should help to infect large areas of the 
tumour. In addition, it was important to determine whether antibiotic treatment also 
reaches the bacteria in the tumour and whether the infective bacteria can still be 
controlled after the initial phase of growth at this site.  
High numbers of bacteria were observed in tumour tissues over a time period of 60 
hrs in mice without antibiotic treatment but were not contained in this tissue. Bacteria 
disseminated to the liver and the spleen of mice, where they replicated rapidly. Two 
possibilities could explain this phenomenon. The tumour tissue could serve as a kind 
of depot and bacteria might be transported continuously via blood or lymph to other 
organs. Alternatively, it is possible that the bacteria enter the bloodstream through 
injuries inflicted to the tumour blood vessels during injection.  
Application of ampicillin resulted in a decrease of the bacterial burden in all tissues 
investigated, although significant numbers of bacteria could still be found. This might 
be due to a time period of treatment too short to be effective. On the other hand, 
69 
some areas of the tumour might not be well vascularized, leading to poor delivery of 
the antibiotic and protection of the residing bacteria.  
Reporter gene expression after L. monocytogenes mediated gene transfer was not 
observed under the conditions employed. Several reasons could account for this 
finding. First of all, from the data presented here, it is not evident that the Listeria 
found in the tumour tissue are located inside the tumour cells. However, intracellular 
location is absolutely essential for efficient gene transfer to occur [60]. This matter 
should be addressed by using immunehistochemistry of infected tumour tissue. 
Furthermore, as discussed above, obviously only a fraction of all bacteria transfer 
their plasmid to the nucleus of the host cell. Higher transfection rates should lead to 
detectable transfer also in vivo. An alternative explanation could be that the innate 
immune system removes cells that were invaded by L. monocytogenes. High 
numbers of neutrophilic granulocytes were found in tumour tissues after infection. It 
is therefore conceivable that infected and potentially transfected cells are killed as 
has been shown for infected hepatocytes [19]. Studies in which neutrophils are 
depleted before infection, e.g. by the use of monoclonal antibodies, should clarify this 
issue.  
Using GFP as a reporter gene in vivo might also have added to the lack of detection 
of in vivo transfected cells. Autofluorescence is high in necrotic tissue. Therefore 
cells that express low levels of GFP protein might have escaped the detection 
because they do not exceed the background fluorescence. Choosing an alternative 
reporter that displays a low background activity, e.g. luciferase as used for Shigella, 
should solve this problem. 
4.3.2 S. flexneri 
As alternative carrier, Shigella flexneri was employed, a bacterium for which in vivo 
gene transfer has been shown before [146; 154]. First, proof of principle was required 
that this bacterium transfers plasmids into the tumour cells that were used in the 
model system. In addition, it was necessary to compare the transfection efficiency 
when lysis was exclusively dependent on the attenuation or when antibiotics were 
added. Three different cell lines were bacteriofected in vitro by either S. flexneri 
∆aroD or S. flexneri ∆dap. First, GFP was used as reporter gene to quantify the 
number of transfected cells and to analyse expression levels.  
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Using the ∆aroD strain, gene transfer to HEp-2, BHK-21 and CT26 cells could be 
demonstrated and differences between transfections with or without antibiotic 
treatment were marginal. Apparently, this strain lyses efficiently in the host cell due to 
its inability to synthesize aromatic amino acids. The ∆dap strain is also able to 
mediate gene transfer into the three cell lines, but is less efficient than the ∆aroD 
strain. Again, no significant differences were observed with or without antibiotics. 
Thus the metabolic attenuation is sufficient to ensure lysis of the bacteria in the host 
cell. 
In the studies by Krusch et al. [88] and in the present work it could be established 
that disruption of the bacterial cell wall is important for efficient gene transfer. 
Therefore, the lower transfection rates mediated by the ∆dap strain compared to the 
∆aroD strain were unexpected, since the mutation in the cell wall synthesis pathway 
should lead to especially efficient lysis of the bacteria and disruption of the cell wall. 
However, for the time being it can not be excluded that the differences in transfer 
efficiency are due to the diverse genetic background. The two bacteria were derived 
from different parental strains which might influence several steps required for gene 
transfer. In agreement with this was that the ∆dap strain was less invasive than the 
∆aroD strain. Grossly, similar results were obtained when luciferase was tested as 
reporter. 
For the in vivo transfer of expression plasmids into tumour tissue, Shigella flexneri 
was first tested for enrichment in tumour tissue after i.v. and i.p. administration. As 
mentioned before, accumulation in tumours has been described for several bacterial 
species. However, no bacteria could be found at any time point in the tissues tested. 
Since Shigella flexneri is not pathogenic in mice, this was not unexpected. Most 
likely, the innate immune system eliminates the bacterium almost immediately after 
administration. This does not necessarily exclude that Shigella can have tumour 
targeting properties in its natural hosts. Therefore, these experiments should also be 
performed in animals that are susceptible for Shigella infection.  
In contrast, direct intratumoural application revealed interesting results. Bacteria 
could survive for an extended period of time, actually much longer than would be 
expected from their behaviour in the in vitro experiments. In addition, bacteria were 
found in spleen and liver under these conditions. This seems to be in contrast with 
the results obtained by i.v. or i.p. injection. Most likely the tumour serves as immune-
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privileged reservoir that is rich in nutrients and from which bacteria can disseminate 
into other tissues.  
In vivo gene transfer was tested using luciferase as reporter. Here, enzymatic activity 
could be detected in tumour lysates. However, the CMV promoter used for 
expression is also active to a certain degree in bacteria. Therefore, the evidence for 
gene transfer can be taken as suggestive but not as compelling. This problem must 
be solved by either taking a promoter that is completely silent in the bacterial carrier 
or by constructing a reporter that can only be active in the host cell. This could be 
achieved for instance by introducing an intron into the reporter gene or by employing 
a reporter whose activity relies on glycosylation. 
The above results call into question the genuineness of the results obtained after in 
vitro bacteriofection using luciferase as reporter. However, in this case, the number 
of viable intracellular bacteria generally decreased from 24 to 48 hrs, while the 
luciferase signal strength increased at the same time points. Taking into account the 
short biological half life of the luciferase protein, which is approximately 2 hrs [63], it 
is sure that the detected luciferase activity was expressed from a plasmid in the host 
cell nucleus after transfer.  
Taken together, from this work it is apparent that intracellular bacteria as gene 
shuttles are still at the initial phase of development. Nevertheless, they have 
attracted already substantial attention. Bacteria as carriers for mucosal DNA 
vaccines are already completely accepted by the scientific community. It can be 
foreseen that improvement of transfection efficiencies in the future will also allow 
such microorganisms to be employed in gene therapy of complex diseases.  
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5 Summary 
Several aspects of bacteria-mediated gene transfer in vitro and in vivo have been 
addressed in this work. First, the mechanisms involved in plasmid transfer from the 
intracellular bacterium L. monocytogenes to eukaryotic host cells were investigated. 
It could be shown that the initial step during bacteriofection, namely invasion of the 
host cell, is not limiting for efficient gene transfer. Furthermore, bacteria are efficiently 
lysed upon antibiotic treatment and release their content to the cytosol. Despite of 
this, it became obvious that only a fraction of the intracellular bacteria transfer their 
plasmid load to the nucleus of the host cell, as was shown by co-transfer of two 
different expression plasmids by L. monocytogenes. Further experiments suggested 
that contrary to the original idea in which the plasmids are simply released upon 
bacterial lysis the plasmids are associated with high molecular weight components. 
However, not only plasmid DNA was transferred to the nucleus of the host cells, but 
also to a small degree bacterial chromosomal DNA was transferred and integrated in 
the host cell genome.  
These findings suggest further studies towards the investigation of the plasmid 
transfer pathway and its rational improvement. Enhancing the transfer efficiencies 
should drastically lower the dose of bacteria required to achieve effective 
bacteriofection and thus render integration of bacterial DNA negligible.  
In the second part of this work, L. monocytogenes and S. flexneri were tested as 
gene transfer vehicles for cancer therapy. The dissemination of both bacteria was 
analyzed after infection via the intratumoural route. Unexpectedly, the bacteria were 
not contained within the tumour tissue but were also found in liver and spleen of 
mice. Viable attenuated Shigella were detected in mice as long as 7 days p.i. 
However, when mice were systemically (via the intraperitoneal or intravenous route) 
infected with attenuated S. flexneri, the bacteria were rapidly cleared from the blood 
stream and did not accumulate in tumours or organs, as described before for other 
bacterial species. 
Gene transfer from bacteria to tumour cells in vivo could not clearly be demonstrated 
for Listeria under the conditions used. In contrast, some implication of gene transfer 
by Shigella was found. Here, refinement of the technical settings should allow the 
definite detection of even low levels of transgene expression and permit distinction of 
eukaryotic and prokaryotic expression. In summary, improvements that will be 
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suggested by extending the present work will result in better gene transfer abilities 
and will reveal the great potential of such bacteria as DNA carriers.  
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